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ABSTRACT 
Salih, Anmar Mahdi M.S.B.M.E. Department of Biomedical, Industrial, and Human 
Factors Engineering, Wright State University, 2019. Characterization of In-Vivo Damage 
in Implantable Cardiac Devices and the Lead Residual Properties. 
 
 
 
Approximately, 92.1 million patients in the US suffer from cardiovascular diseases with 
an estimated healthcare cost of over $300 billion; out of which at least one million patients 
have Cardiac Implantable Electronics Devices (CIED). CIED represented by pacemakers, 
Implantable Cardioversion Defibrillator (ICD), and Cardiac Resynchronization Therapy 
(CRT) are exposed to in-vivo damage. These damages are complex and composed on 
multiple levels and present challenges while assessing their combined extent. Since 2004, 
more than one hundred recalls were reported for cardiac devices. ICD devices had the 
majority with 40.8% recalls, pacemaker recall percentage was 14.5%, CRT recall 
percentage was12.7%, leads recalls were 9.7%, and others (stents and LVAD) with 22.3% 
recalls. The objective of this research is to investigate the damage of the cardiac devices 
and the changes in the residual properties after in vivo implantation, such knowledge will 
lend insight into the common damage patterns, controlling the probability of failure in the 
design of future devices, and improve reliability. In vivo damage assessment was 
performed on 65 retrieved cardiac devices and 136 leads from different manufacturers 
(Medtronic, St. Jude Medical-Abbott and Boston Scientific). The examined damage 
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features were surface deformation, burnishing, pitting, scratching, discoloration, 
delamination, insulation defects, coil damage, and abrasion.  
The results showed that the main damage mode observed was scratching, and the 
anterior side of the Pulse Generator (PG) was more exposed to damage than the posterior 
side. Additionally, the middle part of the lead was more exposed to damage than the 
proximal part. Tensile test was also performed on new and retrieved Medtronic 5076 
CapSureFix Novus MRI SureScan leads. Load to failure showed a significant decrease 
after 18 months of in-vivo exposure (P-value =0.0008). Percentage elongation showed a 
significant decrease after 94 months of in-vivo exposure (P-value<0.0001). Ultimate 
tensile strength showed significant decrease after 73 months of in-vivo exposure (P-
value=0.0339) and percentage elongation at 5N force showed significant decrease after 66 
months of in-vivo exposure (P-value =0.0037). On the other hand, modulus of elasticity 
has direct proportion with the number of in-vivo months and showed significant increase 
(P-value=0.0051) after 73 months of in-vivo environment.  
In conclusion, it can be inferred that the as received pulse generator had mainly 
scratches that were shallow, narrow and could not have affected the functionality of the 
devices. The as received leads had visible insulation defects, stretches, and coil damages 
that could have caused different types of failures and could have affected the functionality 
of the devices. 
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CHAPTER 1: INTRODUCTION 
 
1.1 INTRODUCTION 
A cardiac device is a medical electronic equipment located under the skin at the area of the 
chest or the abdomen to treat the abnormality in heart rhythm. It delivers electrical impulses 
to the heart via the lead [1]. There are several types of biomedical devices that can be used 
as a therapy to tachyarrhythmia and bradyarrhythmia like Implantable Cardioverter 
Defibrillator (ICD) and Pacemaker. These two devices have leads that are implanted either 
in the Right Ventricle (RV) or Right Atrium (RA) depending on patient’s case. A single 
chamber pacemaker or ICD has one lead that passes through subclavian vein to the RA or 
RV, while the dual chamber PM or ICD has two leads, one implanted into the right ventricle 
and the other implanted into the right atrium. Another procedure requires a third lead 
implanted into the Coronary Sinus (CS) to provide Cardiac Resynchronization Therapy 
(CRT). 
The market size of the cardiovascular devices is voluminous, and the number of 
implanted devices is increasing with time. According to Journal of the American College 
of Cardiology, the number of the dual chamber devices were around 520,000 in 2009 
(pacemakers and ICDs) [3], and this number has increased to 1.14 million in 2016, and by 
2023 it is projected to be 1.43 million [4]. The single chamber atrial implantation is 
declining, however; in the USA, physicians prefer to implant dual chamber pacemakers 
[5]. Age of the patients who receive PMs, ICDs, and CRTs devices range 65 ± 14 years 
2 
 
[3], although children also are candidates for such procedure. The hospital charges for 
cardiac devices implantation of CRT is around $110,000 [84]. 
 
1.2 MOTIVATION 
Since 2004, more than one hundred recalls were reported for cardiac devices. ICD devices 
had the majority with 40.8%, pacemaker 14.5%, CRT 12.7%, leads 9.7%, and others (stents 
and LVAD) with 22.3% recalls [6]. Minimizing the risks of failure and reducing emergency 
visits are crucial. Therefore, there is a need to investigate retrieved cardiac devices to fully 
understand damage development and residual properties due to in-vivo exposure. Several 
studies [7, 8, 9, 10] were reported in this area; however, each with limitations. For instance, 
Jacobs et al. [7] performed electrical tests, optical microscopy and Scanning Electron 
Microscope (SEM) on the lead. This study [7] focused only on one manufacturer in their 
experiment. Wiggins et al. [8] used optical microscopy, SEM and Fourier-Transform 
Infrared Spectroscopy (FTIR) to determine the chemical degradation on the inner and outer 
insulation. However, their experiment included only 7 leads. In order to provide significant 
representation for damage development of the cardiac devices through in-vivo 
implantation, a comparison between multiple manufacturers, different damage features, 
and residual properties are needed. To the best of our knowledge, this is the original effort 
in which damage assessments of more than one hundred leads exposed to in-vivo 
environment for up to 16 years from multiple manufacturers was undertaken. In general, 
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this study involved thorough visual inspection, different types of damage, several types of 
lead failure, optical microscope inspection, mechanical testing and electrical tests. 
 In addition to investigating the damage assessments of cardiac devices, there is a 
need to investigate the residual properties of leads after being exposed to in-vivo 
environment. Long-term exposure may lead to catastrophic results depending upon the 
integrity of insulation. Several studies were conducted to evaluate the residual properties 
of the leads to estimate how their insulation degraded and predict the degradation process. 
For instance, Chan et al. [10], investigated three major cardiac device leads by immersing 
these leads in 0.9% normal saline solution for 10 days at room temperature, and performed 
tensile test to obtain their residual properties. Starck et al. [11] used 13 pacemaker leads 
from one manufacturer and categorized these leads into three groups depending on locking 
stylet-used to support the lead and inserted through the coil. All the above mentioned 
studies performed in-vitro experiments. In order to provide a realistic representation of the 
changes in residual properties of lead insulator inside the human body, there was a need to 
investigate retrieved cardiac devices that have been exposed to in-vivo environment for at 
least ten years. Tensile test, visual inspection (after and before the test), and optical 
microscope inspection (after and before the test) were performed to evaluate the 
degradation of the silicone insulation of Medtronic 5076 CapSureFix Novus MRI SureScan 
leads of different in-vivo implantation durations. 
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1.3 THESIS OUTLINES 
This thesis is divided into five chapters. The second chapter provides a comprehensive 
review of cardiac devices. This chapter includes basic background information on cardiac 
devices, components, several lead design aspects, and types of battery materials. In 
addition, several case studies in cardiac device failure were discussed. 
Chapter three presents investigation of retrieved cardiac devices. A thorough in vivo 
damage assessment investigation of retrieved devices was performed. 
Chapter four focuses on the characterization of the residual properties of Medtronic 
5076 CapSureFix Novus MRI SureScan lead with in vivo implantation devices. 
Chapter five summarizes the finding of the thesis. In this chapter, the 
recommendation for future works was discussed. This thesis presents data that will be 
valuable to design of novel cardiac devices, materials, and at the same time improve 
longevity of in-vivo application. 
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CHAPTER 2: BACKGROUND 
 
2.1 PACEMAKER 
Pacemaker is a type of CIED that is located under the skin in the upper chest with lead 
implanted via the vein into the heart. More recently, leadless pacemakers are available 
(Micra-Medtronic) that are implanted directly into the RV via the Femoral veins. It delivers 
electrical impulses to the chambers of the heart via the leads [78]. Pacemakers are used to 
assist patients with sinus node dysfunction, first-, second-, third-AV block, syncope, and 
other diseases [15]. Three types of pacemaker are in use, single chamber, dual chamber, 
and triple chamber pacemaker. 
2.1.1. Single Chamber Pacemaker 
This type of pacemaker has only one lead which is implanted either in the right ventricle 
or the right atrium [16]. This type is used when there is dysfunction of Sino-Atrial (SA) 
node commonly referred to as sick sinus syndrome, Atrio-Ventricular (AV) node, and 
bundle of His (part of the conductive system of the heart which delivers impulses from 
atrioventricular node to the apex of the heart) [2], or Purkinje fibers. The atrial type of 
pacemakers are used to sense the activity in the atrium and pace when needed [79]. Another 
kind of single chamber pacemaker uses the lead, which is implanted in the RV, and treats 
issues with the AV node, bundle of His, or Purkinje fibers [17]. In the case of atrial 
fibrillation (AF), the PM paces the ventricle to keep it as normal pacing as possible without 
tracking the atrium during rapid heart rate [18]. This kind of single chamber pacemaker is 
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used to sense the activity in the RV and to pace the RV when needed [16]. The most 
common modes used in single chamber pacemaker are VVI, VVT, and AAI [5].  
2.1.2 Dual Chamber Pacemaker 
This type of pacemaker has two leads, one is implanted in the RV and the other is implanted 
in the RA, this type is used for patients with SSS and AV block. It monitors the activity in 
both RA and RV and pace when necessary, either in both chambers or one of them [80]. 
2.1.3 Triple chamber (Biventricular) pacemakers 
This type of pacemaker has an additional third lead that is implanted in the coronary sinus 
to pace the left ventricle (LV) and is used for patients with heart failure (HF) with ejection 
fraction (EF) less than 35% who have Left Bundle Branch Block (LBBB) to provide 
cardiac resynchronization. It also is known as CRT-P [20]. 
 
Figure 1 A) Sigle chamber pacemaker, B) Dual chamber pacemaker, C) Triple chamber pacemaker (CRT-P) 
2.2 IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (ICD) 
Implantable defibrillators represent the most significant advance in our ability to prevent 
sudden cardiac death due to ventricular arrhythmias [21]. ICD is a CIED that has the same 
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function as that of a pacemaker; in addition, it is capable of aborting Ventricular 
Tachycardia (VT) or Ventricular Fibrillation (VF) in high-risk patients by delivering 
shocks or Anti-Tachycardia Pacing (ATP) [1]. Three types of ICDs are in use single 
chamber, dual chamber, and triple chamber.  
2.2.1 Single chamber ICD 
This type of ICD has one lead which is implanted in the RV. This lead is different from 
pacemakers’ lead, as it has proximal and coils in addition to provide sensing and pacing 
function. It can provide ATP or deliver high-voltage therapy (shock delivery-up to 41 
joules) to abort VT or VF [22, 80]. The lead has two coils, these coils are used to deliver 
shocks in case the patient needs it. One coil is present in the right ventricle called RV distal 
coil, and the other coil is located in the area of the superior vena cava or SVC coil [22, 80]. 
A totally new concept of ICD was represented by Boston Scientific, Subcutaneous ICD (S-
ICD). S-ICD is now available, where the defibrillator lead is tunneled underneath the skin 
completely avoiding venous access or direct contact with the heart [85]. 
2.2.2 Dual chamber ICD 
This type of ICD has two leads implanted. One in RA for pacing and sensing, and another 
in RV which is capable of delivering of defibrillation and ATP [22]. 
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2.2.3 Triple chamber ICD 
In addition to the leads discussed in section 2.2.3. This triple chamber ICD has a 
defibrillation lead in RV instead of pace/sense lead. Indications for implantation are similar 
to those for section 2.1.3. [23]. 
 
Figure 2 A) Single chamber ICD B) Dual chamber ICD C) Triple chamber ICD (CRT-D) 
 
2.3 CARDIAC DEVICE COMPONENTS 
2.3.1 Battery 
Battery system is one of the most important components of CIED and has been under 
development to increase device longevity and decrease PG size. The early battery used Li 
as an anode with I, MnO2, CFx, Ag2O4V11, and hybrid as the cathode. The batteries are 
either single use like in the pacemaker or multiple uses like in rechargeable batteries. Some 
devices need a special battery in order to provide a better service. Some precautions should 
be taken into consideration for special types of battery applications like power density, 
longevity, and how the battery depletes. Proper chemistry and how to apply these batteries 
were very helpful in the biomedical applications and in treatment [24]. 
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The primary power source for permanent pacemakers was Mercury zinc [25]. These 
types of batteries were used in early pacemakers. The pacemakers could not be 
hermetically sealed as these batteries produced gasses over time that required venting. This 
could lead to fluid accumulation inside the PM and could cause damage to the circuit and 
the PM would not deliver therapy appropriately. Mercury zinc batteries have a short use of 
life and have sharp voltage drop. This makes predicting failure of these batteries difficult. 
No devices of this type are currently in use [21]. 
A. Lithium/iodine batteries 
Cardiac devices need a power source to deliver therapy with small values of current (mAh). 
Li/I2–PVP system was the first battery composition that was patented and used in 1972 
and some devices are still run on this system. Li/I2–PVP cells were the first choice for the 
biomedical application due to their high energy density in a small volume, safety, and 
accuracy. The reaction can be summarized in [26] 
𝐴𝑛𝑜𝑑𝑒: 2𝐿𝑖−
𝑦𝑖𝑒𝑙𝑑𝑠
→    2𝐿𝑖+ + 2𝑒− 
𝐶𝑎𝑡ℎ𝑜𝑑𝑒: 𝑀𝐼2 + 2𝑒
−
𝑦𝑖𝑒𝑙𝑑𝑠
→    𝑀 + 2𝐼− 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛: 2𝐿𝑖 + 𝑀𝐼2
−
𝑦𝑖𝑒𝑙𝑑𝑠
→    𝑀 + 2𝐿𝑖𝐼 
M represents poly-2-vinyl pyridine. 
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B. Lithium/manganese dioxide batteries 
Many medical devices- due to their high performance- require batteries that can deliver 
therapy to patients with a minimum consumption of power. Ikeda promoted the 
lithium/manganese dioxide early type in the 1970s and it is a good fit for these medium 
rate applications [27,28]. Manganese dioxide is also used in zinc carbon cells, but this 
material showed a significant heat treatment which made them a good composition for the 
lithium battery [27][28][29]. The lithium/Manganese dioxide system is used in a high 
number of medical devices due to its high potential, high energy density, and high capacity 
[29].  
𝐴𝑛𝑜𝑑𝑒: 𝐿𝑖−
𝑦𝑖𝑒𝑙𝑑𝑠
→    𝐿𝑖+ + 𝑒− 
𝐶𝑎𝑡ℎ𝑜𝑑𝑒: 𝑀𝑛𝐼𝑉𝑂2 + 𝐿𝑖
+ + 𝑒−
𝑦𝑖𝑒𝑙𝑑𝑠
→    𝐿𝑖𝑥𝑀𝑛𝐼𝐼𝐼𝑂2 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛: 𝑀𝑛𝐼𝑉𝑂2 + 𝐿𝑖
𝑦𝑖𝑒𝑙𝑑𝑠
→    𝐿𝑖𝑥𝑀𝑛𝐼𝐼𝐼𝑂2  
 
C. Lithium/carbon monofluoride batteries 
Another choice for implantable medical devices that need a small output power (0.5V to 8 
V). This choice is the (Li/CFx) system. Carbon monofluoride was early promoted as a 
cathode material in batteries in the 1970s [30][31]. The low discharge values, high potential 
and high density of the LiCFx system have made it helpful for devices that need higher 
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values than expected [32]. Due to its insulation property, CFx is mixed during preparation 
to make the cathode with more storage capacity [33]. During the construction process of 
the cathode and lithium anode, they use an insulator between them. The insulator is lithium 
tetrafluoroborate (LiBF4) that can be dissolved in butyrolactone [32] The reaction is [25]: 
𝐴𝑛𝑜𝑑𝑒: 𝑥𝐿𝑖−
𝑦𝑖𝑒𝑙𝑑𝑠
→    𝑥𝐿𝑖+ + 𝑥𝑒− 
𝐶𝑎𝑡ℎ𝑜𝑑𝑒: 𝐶𝐹𝑥 + 𝑥𝑒
−
𝑦𝑖𝑒𝑙𝑑𝑠
→    𝑥𝐿𝑖𝐹− + 𝑥𝐶 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛: 𝐶𝐹𝑥 + 𝑥𝐿𝑖
−
𝑦𝑖𝑒𝑙𝑑𝑠
→    𝐶 + 𝑥𝐿𝑖𝐹 
Where C represents carbon and x represents variable depending on how fluorine react with 
lithium [25]. 
 
D. Li/CFx–SVO hybrid batteries 
Due to its high energy density which gives them a longer life than expected, these types of 
batteries are used in a wide range of various types of biomedical devices. In order to 
provide a high power, these batteries combine CFx with Ag2V4O11. [34][35]. This type is 
mainly used with ICD and CRT-D (high voltage devices). In addition to all the benefit of 
the hybrid battery, they offer an enhanced end of life detection and alert the patient once it 
reaches the Elective Replacement Interval (ERI).  A comparison between CFx and silver 
vanadium oxide is shown in Fig. 3d [35].  Fig.3 below shows different chemical 
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compositions of batteries, and how these compositions deliver energy to different 
biomedical implantable devices. Fig.3a shows how lithium iodine battery depletes under 
several loads. The loads applied from 4kΩ to 100kΩ [36]. Fig.3b shows 
Lithium/manganese dioxide battery discharge curve [37]. Fig.3c shows the depth of 
discharge of Lithium/carbon monofluoride batteries under several loads [38]. Fig.3d shows 
a comparison between carbon monofluoride and silver vanadium oxide, in addition to how 
these batteries are depleted under same workload [39]. It can be seen that carbon 
monofluoride has a parabolic curve then depleted sharply till the end of service. On the 
other hand, silver vanadium oxide has a sharp decline at the beginning of its service. And 
after 45% of cathode utilization, it starts to be consistent till the end of service. 
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Figure 3 A) Li/I2–PVP discharge under several loads [36] B) LiMnO2 discharge curve [37] C) Discharge LiCFx under 
several loads [38] DOD = depth of discharge D) Comparison between CFx and silver vanadium oxide [39]. 
2.3.2 Circuitry 
The first invented medical devices were containing small resistance, transistor, and 
capacitors built together or placed on circuit board as shown in Fig.4 [2]. New devices are 
now more complex and more integrated CPU systems. They contain RAM and ROM. This 
led in a decrease in size, weight, and power consumption. There has also been a tremendous 
increase in features, reliability, flexibility, and longevity. The newer devices have large 
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data storage capabilities to track the function of the device as well as many different patient 
parameters. The latter includes a total number of cardiac events, the rate of these events, 
whether these were paced or intrinsic, and high rate episodes. The newest devices have the 
ability to store intracardiac electrograms and function as event monitors with the ability to 
playback the paced or sensed events. Fig.5 illustrates the block diagram of modern cardiac 
device circuit [2]. It shows how the device sense/pace the heart through electrodes 
embedded on leads that can filter the obtained waveforms from the heart. These waveforms 
transferred to a programmable logic to analyze it and decide what therapy should be 
delivered via therapy algorithm. Afterwards, these events stored in a memory which then 
can be reviewed by physician. Current generation implantable defibrillators as well as 
“high end” pacemakers are capable of recording actual cardiogram strips during a 
symptomatic episode. These recordings are extremely valuable in diagnosing the cause of 
patient symptoms as related to heart rhythms [21].  
 
Figure 4 Modern Cardiac Device circuitry [2] 
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Figure 5 Block diagram of modern Cardiac device's circuit [2] 
 
2.3.3 Connector Block 
The connector block (also referred to as the “header”) is the means by which the 
pacemaker/ICD wire is connected to the device circuitry. As shown in Fig. 6, there are 
many different sizes and styles of connector blocks. All have in common a method for 
securing the wire to the pacemaker and a method for making a secure electrical connection. 
If the wrong type of connector block is used the wire may not fit into it properly, the wire 
may be loose, and the electrical connection may be intermittent or lost. Any of these can 
result in malfunctioning/nonfunctioning pacing system. Most pacemakers use setscrews to 
both attach the lead to the pacemaker and make the electrical connection at the same time. 
If a bipolar connection (negative and positive on the same lead) is to be made there may be 
one set screw for the anode and another for the cathode (Fig. 6a). As many as eight 
setscrews may be present in a dual chamber biventricular ICD system. Another type of 
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connector uses a setscrew for the distal pin and a spring connector for the ring on the lead 
(Fig. 6b). Finally, some connectors do not use any setscrews (Fig. 6c). These have spring 
connectors for all of the electrical connections and a mechanism for gripping the lead body 
to hold it in place. The advantage of this last system is that it makes the electrical 
connection “automatic” and does not rely on the physician to make a secure connection 
with a screw [21]. 
 
Figure 6 A) Connector block types. Two set screws for each lead (total of 4 in this bipolar dual chamber device), one for 
the anode and cathode. Each screw must be tightened to hold the lead and provide a secure electrical connection. B) 
One set screw for each lead to hold the distal pin (cathode). The anode is connected electrically by a spring-loaded 
band. A unipolar pacemaker would have only a single screw for each lead without the need for an anodal screw or 
spring anode connection. C) Non- screw design uses spring loaded bands to contact both the cathode and the anode. A 
plastic component is pressed in by hand that then grips the lead connector to prevent it from coming out of the 
connector block [21] 
 
2.3.4 Lead 
Leads are wires that connect the cardiac device to patient’s heart. Leads are responsible for 
delivering therapy (low or high voltage therapy) to patient [2]. Several designs of leads are 
available in the market. Lead design can be classified as unipolar, bipolar, and multipolar. 
Unipolar is the earliest lead design and has simple design. It was the only option available 
at that time. It was then replaced by bipolar lead. It has only one coil that connects the pulse 
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generator (PG) to the cardiac muscle and covered by an insulator. The tip of the electrode 
represents the cathode while the PG is the anode. Cathode and anode represent pacing and 
sensing circuit, and it is called unipolar because only one electrode is in touch with the 
cardiac muscle. Because of their design, they show a significant resistance and they last 
longer than expected, some of them still active and some physicians prefer it due to its 
simple design [40]. Unipolar mode is inherently subject to electromagnetic interference 
leading to device malfunction [40]. 
While bipolar leads exclude the pacemaker from the circuit, the circuit contains the 
tip (cathode) and the ring (anode), both are in touch with the cardiac muscle. Bipolar leads 
have many advantages. There are two designs, the co-axial and co-radial. The co-axial, the 
inner conductor has a coil that runs to the cathode and is hollow from the inside to allow 
the guide wire or stylet to pass through it. While the outer conductor runs to the anode 
(ring) directly and both coils are separated by insulation (ETFE), as shown in Fig. 7. The 
lead is in touch with the cardiac muscle by one of the two fixation methods. The active 
fixation uses a kind of helix to attach for the cardiac muscle that can explanted easily 
compared to the passive fixation. The industry uses a four-layer coaxial design of different 
diameters and designs [40]. 
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Figure 7 Pacemaker Lead Design [40] 
ICD leads use a different type of configuration with multiple lumens to cover the 
sensing and defibrillation coils, but it has a larger diameter compared to pacemaker leads, 
as shown in Fig. 8. 
 
Figure 8 ICD Lead Design [42] 
 
CRT leads are designed to pace LV from coronary sinus to provide mechanical 
synchrony. Early in its development, unipolar leads were designed to pace between lead 
tip to PG. Due to inherent problems with Electromagnetic Interference (EMI) these leads 
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were replaced by bipolar and quadripolar leads [40] as shown in Fig.9. Factors limiting 
successful pacing are higher pacing threshold, stimulating of phrenic nerve usually in 
diaphragmatic pacing, and pacing at an undesirable sites. These were mitigated by 
quadripolar leads which provide as many as twenty alternate vectors [40]. 
 
Figure 9 Examples of LV leads. (A) Bipolar (Boston Scientific); (B) helical bipolar (Boston Scientific); (C) bipolar 
(Medtronic); (D) helical unipolar (Boston Scientific); (E) bipolar (Boston Scientific); (F) S-biased bipolar pacing lead 
(Abbott-St. Jude Medical) [40] 
 
2.3.5 Fixation mechanisms  
Fixation is very important due to the therapy delivery depend on it and the lead should be 
fixed firm with the cardiac tissue. There are two types of fixation, different in the shape 
and mechanism of fixation. Passive Fixation (PF) and Active Fixation (AF) as shown in 
Fig.10. The early fixation method was the passive fixation in which electrodes inserted on 
endocardial surface [42]. Passive fixation is not widely used especially in the right 
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ventricle; however, the passive fixation can be held tightly because of the fibrous tissue 
that makes it hard to removing the lead especially after more than a year of implantation 
[42]. The PF tines make the outer diameter of the lead body larger. The pores in the PF 
tines are bigger than the active fixation helix and used for sensing and pacing (cathode). 
The active fixation is different from the PF, it uses helix that embedded into the right 
ventricle and the right atrium as shown in Fig.10 [42]. CS leads in CRT-D are exclusively 
passive as it is in CS lumen and cannot use active fixation at its distal end due to risks of 
perforation. 
 
Figure 10 passive fixation (top) and active fixation (bottom) [42] 
 
 There are markers that can be found at the distal end of the lead. The use of these 
markers as an indicator for lead positioning are made under fluoroscope, and also can be 
used as an indicator for the helix which refers that it is completely inside the cardiac 
muscle. The LV lead fixation is different from the fixation in the RV and the RA. This lead 
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is used to pace the LV for the HF patients. They use different shapes for fixation like spiral 
curves, (J shape) and other curves in order to anchor into the coronary vein and prevent the 
movement of the lead in future for better performance, as shown in Fig.9. During the 
procedure of implantation of the LV lead, the lead is straight but once it is implanted in the 
proper position that provides the best threshold and impedance, the physician will pull the 
stylet or the guide wire to let the lead takes its position [42]. 
2.4 CARDIAC DEVICE MODES 
Pacemaker modes are classified according to the North American Society of Pacing and 
Electrophysiology (NASPE) and British Pacing and Electrophysiology Group (BPEG) The 
PM has some abbreviation of three to five letters. Each letter represents specific chamber 
and specific function [5]. First letter represents which chamber the PM will pace, second 
letter represents which chamber the PM will sense, third one represents the reaction of the 
PM to the sensed episode, fourth and fifth letters represent some features for pacing (rate 
response) and defibrillation (Anti-Tachycardia Pacing). The below table summarizes each 
letter and the use of it [5]. 
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Table 1 Pacemaker Modes [5] 
Letter I Letter II 
Letter 
III 
Letter IV Letter V 
Paced chamber(s) 
Sensed 
chamber(s) 
Response to 
sensing 
PM feature ICD feature 
O=none O=none O=none O=none O=none 
A=atrium A=atrium I=inhibited R=rate modulation P=pace 
V=ventricle V=ventricle  T=triggered S=shock 
D=dual  D=dual   
D=dual (inhibited and 
triggered) 
D=dual (pace 
and shock) 
 
 
In some cases, special modes are used to maximize the benefit of the device. For instance, 
in Atrial Fibrillation (AF) DDI mode is used to prevent unnecessary RV pacing. In this 
mode PM automatically shuts off sensing in the RV when it detects Atrial Fibrillation 
avoiding unnecessary fast ventricular rates, but continues to provide backup pacing in RV.  
When sinus rhythm resumes, the PM switches back to normal functioning providing AV 
sequential pacing giving the maximum length of AV synchrony [43]. Table 2 below shows 
PM modes and what condition these modes are used for. 
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Table 2 Practical Pacemaker Codes [5] 
 
 
 
Code What does it mean Which disease 
AOO Only pacing the atrium SSS with no need to sense in the atrium 
AAI 
Atrial pace, atrial sense, inhibited by 
atrial signals 
SSS 
VOO Ventricular pace, no sense, no inhibit 
3rd degree AV block with AF or temporarily 
during MRI/cautery usage 
VVI 
Ventricular pace, ventricular sense, 
ventricular inhibit 
3rd degree heart block with atrial fibrillation. 
DOO Dual pace, no sense, no inhibitions 
3rd degree AV block or temporarily during 
MRI/cautery usage 
DVI 
Dual pace, ventricular sense, 
ventricular inhibit 
3rd degree heart block with supraventricular 
tachycardias 
DDD Dual pace, dual sense, dual inhibit 3rd degree heart block. 
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2.5 LITERATURE REVIEW 
Pulse generators and leads are vulnerable to failure. This failure can be either mechanical 
or clinical. Clinical failure related to lead insertion approach taken by physician to implant 
the lead. Mechanical failure related to lead insulation, in-vivo environment, and how often 
the device operates. In this section, a summary of previous researches will be introduced. 
 Mechanical failure of leads due to abrasion are the most common problem affecting 
ICD leads [44]. Abrasion arises when the lead comes in contact with the pulse generator at 
the area of the pocket, this type called can abrasion [45]. Furthermore, abrasion happens 
when the lead gets in contact with other lead, called lead-to-lead abrasion [45]. Since 
abrasion could lead to lead failure techniques to prevent such failures are coating the lead 
insulation [44]. One material is silicone-polyurethane copolymer, which is also known as 
Optim (trademark of Abbott). Optim has shown more abrasion resistance than silicone in 
more than 278,000 implanted lead with 99.9% survival after 5 years [46]. Hauser et al [44], 
have studied 15 Riata ST Optim (trademark of Abbott) and 37 Durata leads (trademark of 
Abbott). These 15 leads were exposed to in-vivo environment for 29.1±11.7 months. Eight 
of the 15 leads had can abrasion, and three had lead-to-lead abrasion. One death was 
reported due to this issue [44]. On the other hand, Durata leads were exposed to in-vivo 
environment for 22.2±10.6 months. Twelve out of 37 leads had shown can abrasion, and 
only six had shown lead-to-lead abrasion. No death was reported on this lead. 
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 Another study was conducted to overcome the lead insulation failure. Ellenbogen 
et al [47] investigated the incidence of failure and the survival probability of Medtronic 
6936 Sprint Fidelis ICD lead. This lead characterized as coaxial with bipolar active 
fixation. Medtronic 6936 ICD lead use two insulations, polyurethane 55D covers the inner 
coil, polyurethane 80A covers the middle coil and as outer insulation [48]. This study was 
performed on 76 ICD leads for more than two and half years of clinical follow up. It showed 
37% survival probability at 68.6 months due to noise after shock delivery. This noise was 
caused by the polyurethane insulation after the device delivered a shock to the patient. The 
main reason for this issue is the metal ion oxidation that could cause polyurethane 
breakdown [49][50]. 
 Estimation of Riata lead failure due to insulation breakdown was performed by 
Parvathaneni et al [51]. This study was performed at Vanderbilt University Medical Center, 
Nashville, TN, and the Tennessee Valley Health Systems/VA-Nashville. This study 
included 87 leads, which went under fluoroscopy and checked for any results of 
abnormality after extraction. Results showed that lead failure due to coil damage was seen 
in 29 out of 87 leads, and electrical failure was seen in 19 out of 64 leads. The reason for 
these issues was the insulation, as it can be seen in Fig. 11. Insulation breakdown of Riata 
leads was the main issue. 
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Figure 11 Showing insulation break due to fluoroscopy, and how the coil is damaged [51] 
 
Lead failure can be a crucial issue when it comes in contact with other living tissues 
inside the human body. A study had been conducted to overcome the failure and 
complications of the lead at the level of the tricuspid valve. Erkapic et al [52], studied the 
risk of lead failure at this level. The study was performed on 357 patients who received a 
Riata family ICD leads. 6 leads out of 357 had insulation defect at the level of the tricuspid 
valve and only one lead had insulation defect at the level of SVC, as shown in Fig. 12. 
Device interrogation cannot detect insulation defect due to normal impedance found during 
the follow up. Therefore, physicians must perform routine fluoroscopic evaluation to avoid 
this issue. 
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Figure 12 A) fluoroscopic image shows insulation defect at the tricuspid valve B) the same lead after extraction C) 
fluoroscopic image shows insulation defect at the superior vena cava D) the same lead after extraction [52] 
 
A case study in which a 32 year old male found unconscious in a train [52] had 
Abbott Durata ICD lead. When he proceeded to ER, a discoloration was noted on the pulse 
generator (Fig. 13). Discoloration was caused by inappropriate shock delivered to the 
patient due to can abrasion. Despite the availability of the Optim coating on Durata lead, 
the lead failed due to abrasion at 11 cm away from the pulse generator. 
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Figure 13 A) Pulse generator discoloration B) ETFE abrasion C) External abrasion [52] 
 
Antonelli et al. [53], discussed a new approach of lead failure. They compared lead 
insulation failure depending on the way the lead was inserted and insulation type. Two 
hundred ninety leads were followed for 57±30 months. 116 out of 290 used silicone as an 
insulator, and 174 out of 290 used polyurethane (151 80A and 23 55D).  170 out of 290 
performed by subclavian approach, and 120 performed by cephalic approach. The results 
showed lead insulation failure were found in 13 leads using polyurethane insulation (twelve 
80A and one 55D). 10% with subclavian approach, and 3% when cephalic approach was 
used. The results also showed significant difference in survival (P-value =0.02) between 
polyurethane and silicone. Polyurethane was exposed to more failure than silicone. 
Furthermore, subclavian approach showed 83.2% cumulative survival, and 95.1% survival 
with cephalic approach (P-value =0.03). They concluded [53] silicone leads did not 
experience insulation failure. On the other hand, polyurethane showed insulation failure 
due to abrasion and oxidation degradation. 
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The effects of electrocautery devices on lead insulation examined by Lim et al. [55]. 
Radiofrequency energy was delivered on different levels 10, 20, and 30 watts for 3 and 6 
seconds. Silicone, polyurethane, and silicone-polyurethane copolymer were used in this 
study. Eleven leads and three manufacturers were investigated in this study. New method 
of determining level of insulation damage was presented. They used 0-3 scale (0= no 
damage, 1= slight damage, 2= significant damage, and 3= full insulation damage). Visual 
and microscopic inspection were performed. Significant insulation damage was seen on all 
the leads. Full insulation damage was accompanied with energy of 30 watts. Polyurethane 
has the same thermal damage as in copolymer; on the other hand, silicone did not suffer 
any thermal damage. While mechanical damage was observed on silicone insulation. 
 
Figure 14 A) thermal damage on PU55D B) thermal damage on PU55D C) mechanical damage on silicone [55] 
 
A study by Kron et al. [56] was conducted to determine the survival probability of 
leads and pulse generator depending on some criteria. For instance, lead survival 
probability was determined depending on three types of failure, dislodgment, infection, and 
lead fracture. On the other hand, pulse generator survival probability was determined 
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depending on the location of implantation, pectoral versus abdominal. 539 patients were 
enrolled in this study. The results showed that abdominal pocket had 13% failure, while 
pectoral pocket had 6% failure (p<0.02), as shown in Fig. 15a. Additionally, lead fracture 
was seen more than lead dislodgment, as shown in Fig. 15b. 
 
 
Figure 15 A) survival probability by location of pulse generator B) survival probability by lead failure type [56] 
 
A case study was presented discussing the early abrasion of silicone insulation by 
Ząbek et al. [57]. Biotronik Setrox S53 lead was implanted and after 13 months of in-vivo 
environment, this lead failed. This lead failed due to “subclavian crush syndrome”, where 
the lead is in contact with first rib and the clavicle [58].  
Kołodzińska et al. [59], introduced how macrophages can affect the level of 
biodegradation. and it can be concluded that the biodegradation was initiated by the tearing 
around the surface of the lead.  
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Residual properties of leads were the most challenging studies. Few studies 
presented how residual properties deteriorating with in-vivo environment. For instance, 
Wilkoff et al. [60] studied three different insulations- Optim, P55D, and silicone elastomer. 
These leads categorized into three different in-vivo years (zero year, 2-3 year, and 4-5 
year). Afterward, tensile test was performed to obtain the maximum load and extension. 
Results showed that Optim molecular weight decreased 20% after 2-3 years, then remained 
unchanged for 4-5 years. On the other hand, tensile strength decreased 25% after 2-3 years 
then stabilized for 4-5 years. Furthermore, elongation did not change at all. Molecular 
weight of polyurethane was not exposed to any changes during that period. Silicone 
showed significant biostability compared to polyurethane and Optim. 
Chan et al. [10] studied Boston Scientific’s FINELINE II STEROX 4456, 
Medtronic’s CAPSURE SENSE 4074, and Abbott’s ISOFLEX OPTIM 1948 leads. These 
leads exposed to in-vitro environment. They immersed the leads in 0.9 normal saline 
solution at room temperature for 10 days. Afterward, tensile test was performed. Boston 
Scientific’s lead and Medtronic’s lead showed same tensile strength; however, Abbott’s 
lead showed lower tensile strength than BSX and MDT leads (p<0.001). This is an in-vitro 
study accelerated with time, and the in-vivo studies are totally different.  
Starck et al. [11] categorized the leads in groups according to testing method used. 
First group was performed without central supporting stylet, second group was performed 
with central supporting stylet, while third group was performed with supporting stylet and 
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compression coil. Stylet and compression coils are used as a support to the lead. Stylet and 
compression coils are inserted inside the lead. Results showed tensile strength for group 
one was 28.3±0.3 N, for group two was 30.6±3.0 N, and for group three was 31.6±2.9 N. 
Modulus of elasticity for group one was 22.8±0.1 MPa, for group two was 2830.8±351.1 
MPa, and for group three was 2447±510.5 MPa. This study introduced the supporting stylet 
that can enhance mechanical behavior of leads insulation. 
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CHAPTER 3 INVESTIGATION OF RETRIEVED CARDIAC 
DEVICES 
 
3.1 INTRODUCTION 
Cardiovascular diseases (CVD) are among the leading causes of mortality globally, 
especially in the developed countries [61]. While 17.3 million mortalities occurred from 
CVDs in 2008, it is projected to increase to 23 million by 2030 [62]. In the United States 
alone, about 92.1 million adults have cardiovascular disease with an estimated health-care 
cost of over $316 billion [62]. There are more than 1 million people around the world with 
implantable devices for cardiac conditions and quarter of these devices in the United States 
[63]. These numbers are projected to be increased many-folds with time and might reach 2 
million in the US alone. A pacemaker delivers electrical impulses via electrodes causing 
the heart muscles to contract and regulate the heart beating.  Therefore, there is a need to 
understand how these devices deteriorate after implantation so that corrective actions can 
be taken and in vivo performance enhanced. 
Overall, the vast majority of the described cardiac devices consist of the pulse 
generator which is the body of the device and the leads [64]. The pulse generator contains 
the circuit board and the battery, it stores data such as a total number of cardiac events, the 
rate of these events, whether these were paced or intrinsic, and high rate episodes. 
Moreover, cardiac devices offer the ability to store intracardiac electrograms and function 
as event monitors with the ability to playback the paced or sensed events. These recordings 
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are extremely valuable in diagnosing the cause of symptoms as related to heart rhythms. 
On the other hand, the other major component that constitutes the cardiac devices is the 
leads. The leads are specially engineered wires that are designed to connect the pulse 
generator to the heart muscle. An electrical signal is transmitted through the leads allowing 
the pulse generator to sense and pace the heart whenever an abnormal behavior is detected. 
To prevent the electrical signal from travelling to other places, the leads are encased in an 
insulator which is made either from silicone or polyurethane [64]. In addition, the length 
of the pacemaker leads typically vary from 45 to 85 cm and the number of leads that are 
used depends on the type of the cardiac device implanted and of the heart failure symptoms 
to be monitored [64]. Generally, the malfunctions are defined as failure to pace or sense, 
or both, or failure to detect life threatening events and provide inappropriate shock which 
may be caused by problems with battery, the leads, the outer metal case, or the electronic 
components of the main circuit.   
3.2 METHODOLOGY 
The as received-devices were cleaned and sanitized for visual inspection. Serial numbers 
of the devices were tabulated.  The inspection of the pulse generator carried out on the 
anterior and the posterior surfaces, Fig.16. The pulse generators were checked for 
scratches, surface deformation, pitting, discoloration, abrasion, and burnishing. 
Additionally, the leads were divided into three areas of inspection, the proximal part where 
the lead is connected to the connector block of the pulse generator, the middle part known 
as the conductor, and the distal part where the electrode is located and connects the lead to 
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the cardiac muscle, as shown in Fig. 17. Then these leads were checked for surface 
deformation, burnishing, pitting, scratching, delamination, insulation defect, coil damage, 
and abrasions. 
 
Figure 16 Anterior and Posterior side of the pulse generator 
 
The damage modes identified as surface deformation was described by any minor 
or major warping that can be found on the surface of the device. Pitting described as a small 
hemispherical material loss that found on the surface of the device by corrosion. Scratches 
described as two-dimensional array lines as a result of rubbing. Abrasion described by 
shredding in the device materials. Discoloration was a change in the appearance (color) of 
the surface [65]. Insulation defect was described by a surface cracking on the surface of 
the lead or by complete insulation fracture. Coil damage described a cut in the coil 
protruding out of insulation or even damaged within the insulation [66].  
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Figure 17 Lead as received from MDT, showing proximal, middle and distal parts 
 
A damage scoring method was developed to represent damage in terms of 
individual damage fractions, added linearly to produce a total damage score for the pulse 
generators and leads. Three investigators performed the scoring method. These 
investigators received training of four hours to identify the damage modes to determine a 
composite score. The severity of different damage modes identified. Each damage mode 
was rated from 0 to 10 with regards to severity, and how deep the damage is, taking into 
consideration length and width of the damaged area. Where 0 meant no damage and 10 
meant failure. For minor or superficial damages like shallow scratches, depending on the 
length, depth and the number of the scratches the rate was given from 1 to 5. On the other 
hand, the deep scratches that can be felt with the fingers were given a score of more than 5 
based on the length, depth and the number of scratches. In cases where the device was 
37 
 
totally damaged and can affect the normal functionality of the device a total failure to pace 
or sense, the assigned values were from 7 to 10. Damage modes can interact and propagate 
to another type of damage. Depending on the severity of the damage, one damage could 
transform to another. For instance, in pulse generator, severe scratches could propagate to 
pitting and vice versa. In leads, abrasion could transform to insulation defect, and scratches 
could lead to pitting, which could turn to insulation defect as well. 
The damage score equation for the pulse generator was developed to determine the 
damage percentage for each mode. The equation is as follow: 
𝑃𝑢𝑙𝑠𝑒 𝐺𝑒𝑛𝑒𝑟𝑎𝑡𝑜𝑟 𝑇𝑜𝑡𝑎𝑙 𝐷𝑎𝑚𝑎𝑔𝑒 𝑆𝑐𝑜𝑟𝑒 = ∑∑ 
𝑛
𝑦=1
2
𝑥=1
𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒𝑥𝑦 
Where x= 1 through 2 and represents the anterior and posterior surfaces of the device, and 
y represents the damage mode where y=1 through 6. 
y =1 Surface Deformation 
y =2 Discoloration 
y =3 Scratching/Indentation 
y =4  Burnishing 
y=5 Pitting  
y=6 Abrasion  
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The results showed the average total damage score for the pulse generator was 
0.502 ± 0.28. Then, the damage score equation for the lead was developed to determine the 
damage percentage for each mode. The equation is as follow: 
𝐿𝑒𝑎𝑑 𝑇𝑜𝑡𝑎𝑙 𝐷𝑎𝑚𝑎𝑔𝑒 𝑆𝑐𝑜𝑟𝑒 =∑∑ 
𝑛
𝑦=1
2
𝑥=1
𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒𝑥𝑦 
Where x= 1 through 2 and represents the three parts of the lead (proximal, middle and 
distal) of the devices, and j represents the damage mode where y=1 through 9. 
y =1 Surface Deformation 
y =2 Discoloration 
y =3 Insulation Defect 
y =4 Scratching/Indentation 
y =5 Burnishing 
y =6 Abrasion/Grooving 
y =7 Coil Damage 
y=8 Delamination 
y=9 Pitting 
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The results showed the average total damage score for the leads was 0.501 ± 0.29. 
These two equations characterize the accumulative damage made by each mode, and 
accounting for each part of the pulse generator and the lead. For the pulse generator, the 
number of the parts was two while the number of the damage modes varied according to 
different modes. For the lead, the number of the parts was three and the number of the 
damage features changed according to the equation above. All the devices were optically 
examined under the optical microscope. Most of the pulse generators had scratches; 
however, with the naked eye it was not possible to quantify how deep they were. With the 
use of the microscope, the coils were examined for cut, stretches and other damage modes. 
Devices were interrogated at Miami Valley Cardiology Clinic and checked the 
internal components, parameters, remaining longevity, lead impedance, pacing, sensing 
threshold, time of implant, estimated time of retrieval and other information. The lead trend 
shows the impedances during the in-vivo life of the lead ranged 200-2000Ω for the pacing 
lead and 20-200Ω for the defibrillator lead. These impedances were measured to ensure the 
lead integrity to deliver therapy to the patient. 
Each damage mode could cause specific failures to the leads and cause abnormal 
functionality. The failure of the lead is indicated by the one or more of the following 
failures: failure to capture, failure to sense, impedance out of range, conductor failure, 
extra-cardiac stimulation, cardiac perforation, lead dislodgement, and insulation defect [67, 
68]. Failure to capture (loss of capture) is intermittent or complete failure of the lead to 
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stimulate the heart during a specific time programmed previously (mostly outside the 
refractory period). Failure to sense (loss of sensing) can be described as intermittent or 
complete failure of the lead to sense the intrinsic cardiac signal during the specific time 
programmed previously. Impedance out of range can be described as the impedance below 
200Ω or above 2000Ω for the pacing lead and below 20Ω or above 200Ω for the 
defibrillator lead. Conductor failure can be seen either by the naked eye or electrically 
measured if mechanical break of the conductor occurred. Extra-cardiac stimulation occurs 
when the lead senses signal from other chambers and considers it as R-wave and may lead 
to inappropriate shock delivery. Cardiac perforation occurs when the lead tip penetrates 
through the myocardium and it can be observed visually and clinically. Lead dislodgement 
may be described as a spacing taken place between the lead tip and the cardiac muscle that 
could lead to inappropriate lead performance. Insulation defect can be described as an 
evidence of interruption or break in insulation [67, 68]. In order to check for extra-cardiac 
stimulation, cardiac perforation, and lead dislodgement, the distal part must be presented 
for examination. However, the other types of failures were observed in the proximal and 
the middle part of the lead.  
3.3  RESULTS 
3.3.1  Pulse Generator 
The pulse generators of all the manufacturers are made of commercially pure titanium [69]. 
However, titanium accrues damage by scratching and discoloration as most devices 
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sustained scratching, Fig. 18a. 68% of the anterior surface of MDT devices, 66% SJM and 
53% of BSC were scratched. The posterior surface of SJM showed no scratching on the 
surface, while 44% of MDT and 33% of BSC devices exhibited scratching. Surface 
deformation, as shown in Fig. 18b was also found on both surfaces. The anterior surface 
sustained higher deformation than the posterior surface. Discoloration was only found on 
BSC and MDT anterior and posterior surfaces, as shown in Fig. 18c. While burnishing was 
only found on the posterior surface of BSC devices. There were only three SJM devices 
and cannot be included in statistical analyses. All the damage modes are summarized in 
Fig. 19 illustrating the number of devices examined for each of the manufacturers, degree 
of surface deformation, scratching, burnishing, and discoloration on the anterior and 
posterior surfaces. 
 
Figure 18 Pulse Generator Damage Modes, (a) Scratch, (b) Surface Deformation, (c) Discoloration 
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Figure 19 Pulse Generator Inspection, showing the percentage damage for each manufacturer 
The damage modes of the pulse generator were compared to each other by using 
Fisher’s LSD student test using JMP software. The scratching mode showed a significant 
difference when compared to the other damage modes. This test also showed no significant 
difference between surface deformation, pitting, discoloration, burnishing, and abrasion. 
The anterior and the posterior surfaces had compared to each other by using Fisher’s LSD 
student test. The results showed a statistically significant difference between the anterior 
and the posterior surface (P-value =0.0011). Finally, the manufacturers were compared to 
each other by using Fisher’s LSD student test, the results showed a significant difference 
for MDT when compared to BSC and SJM (P-value =0.0399). The damage modes of the 
pulse generator compared to each other by using Fisher’s LSD student test. It showed a 
significant difference between scratching on the anterior and the posterior part. Also, the 
results showed a significant difference between scratching and other damage modes. The 
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pulse generator damage scoring distribution showed that the damage was between 10% 
and 70%. Higher number of devices with 10% damage, however, as percentage damage 
increased to 70%, number of devices decreased. Fig.20 illustrates cumulative distribution 
and total damage score. 
 
Figure 20 PG Damage Score Distribution 
 
The battery life was checked using the corresponding program of each cardiac 
device, and the reports were obtained. Their longevity and the voltage were measured. A 
comparison was made between the battery depletion rate from the product reports. Using 
Ohm meter and the multi-meter, we observed that most batteries were depleted due to in 
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vivo usage of our as received devices. Fig.21 shows a sample report, and how the device 
longevity was estimated. 
 
Figure 21 Sample report of device interrogation, and how device longevity was estimated 
 
3.3.2  Lead 
The leads showed visible cuts and stretches. The coaxial wires were stretched along with 
cuts. Optical microscope was able to resolve cuts and stretches under the insulation. The 
inner coil was also frayed in some parts and had numerous breaks. The coax wire on most 
of the devices was detached out of the insulation and appeared brittle, and in some 
occasions, broken easily. The distal parts of the leads were not retrieved during extraction 
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and submitted to us for investigation. For the pacing leads, the damage modes observed on 
both proximal and middle parts were abrasion (Fig.22a), discoloration (Fig.22d), 
scratching, coil damages (Fig.22b) and insulation defect (Fig.22c). The proximal part 
showed fewer damage than the middle part. Abrasion and discoloration on MDT and BSC 
leads were significant compared to SJM, where no abrasion and discoloration found in the 
proximal part. On the other hand, for the middle part, discoloration, coil damage, and 
insulation defect were highly present on SJM leads compared to MDT and BSC. The ICD 
leads showed more abrasion, scratching and insulation defect in the proximal part than the 
middle part. BSC had the most abraded and scratched leads when compared to MDT and 
SJM. SJM, BSC and MDT leads had almost equal insulation defect. For the middle part of 
the lead, discoloration was only found on MDT leads, and insulation defect was found on 
both MDT and BSC. SJM had only one lead in our inventory and this lead had no damage 
on both the proximal and the middle parts. MDT leads showed no damage, 71.43%, on the 
proximal part and 85.71% on the middle part, and BSC leads showed no damage 83.33% 
on the middle part. Even though the availability of the CRT devices in the lab is from both 
MDT and BSC, but all the leads used were only from MDT of three different types. On the 
proximal part, discoloration, scratching and insulation defect shared the same percentage 
with 6.67%. While this percentage increased significantly in the middle part, in addition to 
coil damage. The percentage of the undamaged parts in the proximal part was higher than 
the percentage in the middle part of the lead. The damage modes are summarized in Fig.23. 
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The damage modes of the lead were compared to each other by using Fisher’s LSD 
student test using JMP software. The insulation defect showed a significant difference 
when compared to the other damage modes, and it showed a significant difference between 
discoloration, abrasion and coil damage. Then the proximal and the middle parts were 
compared to each other by using Fisher’s LSD student test where the results showed a 
statistically significant difference between the proximal and the middle parts (p-
value<0.0004). Also, the results showed no significant difference between discoloration in 
the middle part, coil damage in the middle part, insulation defect in the proximal part and 
abrasion in the proximal part. Finally, damage modes compared for the leads and it shows 
a significant difference between SJM insulation defect and other damage modes for both 
MDT and BSC. It also showed no significant difference between BSC insulation defect, 
MDT insulation defect, SJM discoloration, BSC abrasion, and SJM coil damage. 
 
Figure 22 Samples of Lead Damage Modes, (a) Abrasion, (b) Coil Damage, (c) Insulation Defect, (d) Discoloration 
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The lead damage scoring distribution illustrates that the damage was between 0.1 
and 1. The average damage on leads ranged between 0.1-0.3 damage score. With the 
increment of the damage score the number of damaged leads decreased, where 17.6% (24 
out of 136) of leads with total damage. Fig.24 shows cumulative distribution of the leads 
and total damage score. 
 
Figure 23 Lead Inspection, showing the damage modes versus different leads for different manufacturers 
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Figure 24 Lead Damage Score Distribution 
 
All the above-mentioned damage modes could lead to several types of lead failure. 
These failures could affect the function of the device and may not deliver therapy 
appropriately. These types of failure can be failure to sense, failure to capture, impedance 
out of range and conductor fracture. Failure to sense can be defined as the device is unable 
to detect the intrinsic cardiac signal [68]. Failure to capture can be described as the device 
fails to stimulate the cardiac tissue [68]. Impedance out of range can be described as >30% 
fluctuation in the impedance measured (pacing leads impedance 200Ω-2000Ω, ICD lead 
impedance 20Ω-200Ω). Conductor fracture can be defined as a mechanical damage within 
the lead coils or/and electrodes [68]. 
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Failure to capture can be a result of insulation defect, coil damage, and/or 
scratching. One or more damages can lead to this type of failure. Statistical analysis using 
JMP software was performed to validate the mathematical expression of failure to capture. 
Fig.25 shows the experimental results versus the predicted results (calculated using 
equation below). The analysis of experimental versus predicted results showed statistically 
no significant difference. Therefore, our proposed equation can be used to predict leads 
failure to capture. A failure to capture equation is developed and as follow: 
𝐹𝑎𝑖𝑙𝑢𝑟𝑒 𝑡𝑜 𝐶𝑎𝑝𝑡𝑢𝑟𝑒 =∑𝐷𝑎𝑚𝑎𝑔𝑒 𝑀𝑜𝑑𝑒
3
𝑥=1
 
x =1 Insulation Defect 
x =2 Coil Damage 
x =3 Scratching/Indentation 
 
Figure 25 Failure to Capture Experimental vs Predicted score 
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Impedance out of range can be a result of insulation defect, abrasion, coil damage, 
and/or scratching. One or more damages can lead to this type of failure. Statistical analysis 
using JMP software was performed to validate the mathematical expression of impedance 
out of range. Fig.26 shows the experimental results versus the predicted results (calculated 
using equation below). The analysis of experimental versus predicted results showed 
statistically no significant difference. Therefore, our proposed equation can be used to 
predict leads impedance out of range. Impedance out of range equation is developed and 
as follow: 
𝐼𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒 𝑜𝑢𝑡 𝑜𝑓 𝑟𝑎𝑛𝑔𝑒 =∑𝐷𝑎𝑚𝑎𝑔𝑒 𝑀𝑜𝑑𝑒
4
𝑥=1
 
x =1 Insulation Defect 
x =2 Abrasion/Grooving 
x =3 Coil Damage 
x =4 Scratching/Indentation 
 
 
Figure 26 Impedance out of range Experimental vs Predicted score 
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Conductor fracture can be a result of insulation defect, abrasion, coil damage, 
and/or discoloration. One or more damages can lead to this type of failure. Statistical 
analysis using JMP software was performed to validate the mathematical expression of 
conductor fracture. Fig.27 shows the experimental results versus the predicted results 
(calculated using equation below). The analysis of experimental versus predicted results 
showed statistically no significant difference. Therefore, our proposed equation can be used 
to predict leads conductor fracture. Conductor fracture equation is developed and as follow: 
𝐶𝑜𝑛𝑑𝑢𝑐𝑡𝑜𝑟 𝑓𝑟𝑎𝑐𝑡𝑢𝑟𝑒 = ∑𝐷𝑎𝑚𝑎𝑔𝑒 𝑀𝑜𝑑𝑒
4
𝑥=1
 
x =1 Insulation Defect 
x =2 Abrasion/Grooving 
x =3 Coil Damage 
x=4  Discoloration  
 
Figure 27 Conductor Fracture Experimental vs Predicted score 
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Failure to sense can be a result of insulation defect, coil damage, and/or scratching. 
One or more damages can lead to this type of failure. Statistical analysis using JMP 
software was performed to validate the mathematical expression of failure to sense. Fig.28 
shows the experimental results versus the predicted results (calculated using equation 
below). The analysis of experimental versus predicted results showed statistically no 
significant difference. Therefore, our proposed equation can be used to predict leads failure 
to sense. A failure to sense equation is developed and as follow: 
𝐹𝑎𝑖𝑙𝑢𝑟𝑒 𝑡𝑜 𝑆𝑒𝑛𝑠𝑒 = ∑𝐷𝑎𝑚𝑎𝑔𝑒 𝑀𝑜𝑑𝑒
3
𝑥=1
 
x =1 Insulation Defect 
x =2 Coil Damage 
x =3 Scratching/Indentation 
 
Figure 28 Failure to Sense Experimental vs Predicted score 
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According to the characterization of operational parameters, SJM showed higher 
failure types than MDT and BSC with 50% of its devices. The three manufacturers shared 
the same conductor fracture rate. Fig.29 shows the types of failure and the distribution of 
each type for each manufacturer, neglecting lead types. The number of leads that were 
investigated was 136, of which 102 were manufactured by MDT, while the rest were form 
BSC (28 leads), and SJM (6 leads). The results show that BSC leads had higher failure than 
MDT by 10% with respect to failure to sense, failure to capture and impedance out of range. 
The two most widely used pacing leads were taken and examined thoroughly to identify 
the types of failure modes. These leads were MDT 5076 CapSureFix Novus and BSC 4470 
FINELINE II. The results showed the percentage of leads fail to sense, capture and 
impedance out of range were higher in BSC 4470 (25.00%) than MDT 5076 (15.69%). The 
conductor fracture in MDT 5076 was 6.67% compared to 8.7% in BSC 4470. Insulators 
for MDT was Silicone (MED-4719) [67], while BSC 55D polyurethane [70]. The two most 
widely used ICD leads were taken and inspected carefully to categorize the failure types, 
the leads are MDT 6947 Sprint Quattro Secure and BSC 0157 ENDOTAK RELIANCE. 
The percentage failure of MDT 6947 was lower than the percentage failure of BSC 0157 
with 33.33% for MDT 6947 and 42.86% for BSC 0157, while no lead exposed to conductor 
fracture. MDT used polyurethane as the outer insulator and silicone rubber as inner 
insulator [40], while BSC silicone rubber as the lead insulator [40]. Therefore, three MDT 
CRT leads were examined to identify the types of failure. The three inspected leads were 
4196 Attain Ability, 4194 Attain OTW and 4193 Attain OTW. The results showed that the 
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4196 Attain Ability lead had a lower failure rate than the other leads as well as no conductor 
fracture. All 4194 Attain OTW leads failed due to the damage modes discussed previously. 
While 50% of the 4196 and 4193 leads exhibited no damages. Fig.30 summarizes the 
failure types and the percentage that occurred to the pacing, ICD and CRT leads. 
 
Figure 29 Types of Failure Mechanisms in Leads, showing the percentage of each failure type for each manufacture 
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Figure 30 Types of Failure Mechanisms in leads, showing the comparison between the pacing and the ICD leads of 
MDT and BSC, and three MDT CRT leads. 
 
40 out of 65 devices were still functioning and have a range of longevity from 3 
months to 132 months. These devices are listed in Appendix I. Two of the active devices 
were connected to an oscilloscope to examine the functionality of these devices. The output 
waveform from the leads was measured. Fig.31 represents the obtained waveforms that 
verify the functionality of the device.  
A worse case analysis of pulse generator survival for both MDT (n=37) and BSC 
(n=11) is shown by Kaplan-Meier curves in Fig. 32. The cumulative survival is 71% at one 
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year for both MDT devices and BSC devices, and 10% at six years for BSC devices and 
10% at seven and half years for MDT devices. Pacemaker showed 88% and 91% survival 
rate after one year of implantation for BSC and MDT respectively. After four years, 
however, the survival reduced to 42% for MDT and 38% for BSC from the as received 
devices. No survival for BSC after six years of implantation, while 20% survival for MDT 
pacemakers. The survival probability of the as received damaged leads for both MDT 
(n=53) and BSC (n=9) is shown in Fig. 33. After 60 months, the survival is 60% for MDT 
and 68% for BSC. The survival is 6% for MDT and 25% for BSC after 160 months of 
implantation, and no survival for BSC after 176 months of implantation, while MDT is 6% 
survival after 180 months after implantation. 33% of BSC devices use MDT leads for 
different purposes. 
 
Figure 31 Pulse width and the Voltage, obtained by connecting the devices to an oscilloscope 
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Figure 32 Kaplan-Meier analysis of survival of (A) Medtronic Devices (n=24) and Boston Scientific Devices (n=11), (B) 
Medtronic Pacemakers (n=13) and Boston Scientific Pacemakers (n=8). 
 
Figure 33 Kaplan-Meier analysis of survival of (A) Medtronic Pacing Leads (n=34) and Boston Scientific Pacing Leads (n=9) 
A B
Years Years
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Sensitivity can be defined by the capability of the device to sense the intrinsic 
heartbeat. It represents the minimum cardiac signal that can be sensed by the pacemaker to 
initiate or terminate the therapy. The sensitivity is measured in millivolts, the higher 
sensitivity the lower voltage programmed. When programming the sensitivity to a low 
value, in turn allows the device to sense additional signals than expected and could cause 
what is known as over-sensing. When programming the sensitivity to a higher value, 
prevents the device from detecting the intrinsic cardiac signal and could cause what is 
known as under-sensing.  
Fig.34 illustrates the sensitivity distribution for all the investigated devices. The 
mean sensitivity is 1.188 mV and ranges from 0.25-4 mV. Additionally, the mean 
sensitivity value of the ventricular leads was 1.465 mV and ranged from 0.3-2.8 mV. 
Furthermore, the mean sensitivity value of the atrial leads was 1.188 mV and ranged from 
0.25-4 mV. Fig.35 shows the difference between the sensitivity setting of the ventricular 
and atrial leads, and it shows the ventricular sensitivity setting was higher compared to the 
atrial sensitivity setting.  
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Figure 34 Sensitivity Distribution for all the leads 
 
Figure 35 Sensitivity Distribution for both ventricular and atrial leads 
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3.4 MONTE CARLO SIMULATION 
It is important to understand the effect, or the risk associated with the lead from the devices 
that we have in our lab. Our devices were received posthumously from diseased patients. 
So, it’s important to perform the risk analysis for the leads, and Monte Carlo simulation is 
one of the tools that is used to understand the risk associated for the reliability purposes. In 
order to apply MCS, it’s important to understand the data that we have for the leads in our 
lab, that we want to plot on a run chart and fit some statistical distribution to those data, 
and the best fits were found normal, lognormal, Weibull and gamma. In order to predict 
the probability of failure for large number of devices, Monte Carlo simulation was used. 
First, a domain was defined from the scoring method for the damage modes to determine 
the input of the simulation. These inputs were determined randomly relying on the 
probability distribution for the chosen domain. Second, Monte Carlo simulation was 
performed to predict the percentage failure of the devices and leads. Monte Carlo 
simulation used to produce 200, 500, 1000, 2000, 5000, and 10000 random variables data 
normally distributed within the mean and the standard deviation. Finally, generating a code 
using Matlab to compute the failure probability of pulse generators and leads were 
performed. Fig. 36 shows the predication data of 10,000 random values. The most 
conservative probability of failure distribution was taken predicate the failure rate for 
10,000 devices. It shows ICD leads have significant failure to sense/capture compared to 
pacing and CRT leads (P-value=0.0052). This figure shows that the ICD leads failed to 
capture/sense with minor failures or damages. Then, it was consistent at 75% of failure 
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probability with 80% of damage. Another monte carlo simulation was performed for 
10,000 random variables to predict the impedance out of range as shown in Fig.37. It shows 
CRT leads have significant impedance out of range compared to ICD and pacing leads (P-
value=0.031). It shows that ICD and pacing leads probability of failure are high with 
minimum damage. On the other hands, it shows that CRT leads probability of failure is 
low compared to the same damage/failure of the ICD and pacing leads. Finally, monte carlo 
simulation was performed to predict conductor fracture for 10,000 random variables as 
shown in Fig38. It shows pacing leads have significant conductor fracture compared to 
ICD and CRT leads (P-value=0.0249). It shows the probability of failure of pacing leads 
are higher than the probability of failure of ICD and CRT leads for the same percentage of 
damage/failure. 
 
Figure 36 Monte Carlo Simulation for 10,000 random data For Failure to capture/sense 
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Figure 37 Monte Carlo Simulation for 10,000 random data For Impedance out of range 
 
Figure 38 Monte Carlo Simulation for 10,000 random data For Conductor Fracture 
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Additionally, Monte Carlo simulation was performed to investigate the probability 
of failure of pacing, ICD, CRT leads with respect to different failure types. Student’s T-
test was performed to check for significance difference. The results showed that for pacing 
leads, conductor fracture has statistically significant difference than other failure types (P-
value<0.0001). For ICD leads, results showed no significant difference between the four 
types of lead failure (P-value =0.1101). For CRT leads, there was significant difference 
between failure to capture/sense and other failure types (P-value =0.0015). Fig.39, Fig.40, 
and Fig.41 illustrate monte carlo simulation for 10,000 random data.  
 
Figure 39 Monte Carlo Simulation for 10,000 random data for Pacing leads with respect to type of failure 
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Figure 40 Monte Carlo Simulation for 10,000 random data for ICD leads with respect to type of failure 
 
Figure 41 Monte Carlo Simulation for 10,000 random data for CRT leads with respect to type of failure 
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3.4 DISCUSSION  
In literature the pulse generator of the cardiac device has rarely been investigated for 
damage. Most of the investigations were done on the leads. Discoloration was due to 
titanium oxide resulting in the white color and could have led to further biodegradation. 
The discoloration on the cases do not affect the functionality of the devices. However, it is 
likely that corrosion mechanisms and ions may dissolve in body fluids and their 
pathophysiology is outside the scope of this research. The percentage damage mode present 
on the pulse generator is shown in table 3. The damage percentage on the anterior part is 
61.93% and on the posterior part is 38.07%. 
Table 3 Pulse Generator Damage Mode Percentage, average damage and standard deviation 
  Damage Mode Damage percentage Average SD 
  
P
u
ls
e 
G
en
er
at
o
r 
A
n
te
ri
o
r 
Surface Deformation 13.02% 0.47 1.03 
Pitting 0.00% 0 0 
Scratching 46.41% 1.63 1.63 
Burnishing 0.00% 0 0 
Abrasion 0.00% 0 0 
Discoloration 2.50% 0.1 0.46 
P
o
st
er
io
r 
Surface Deformation 2.17% 0.08 0.38 
Pitting 0.00% 0 0 
Scratching 33.56% 1.16 1.63 
Burnishing 0.67% 0.02 0.21 
Abrasion 0.00% 0 0 
Discoloration 1.67% 0.06 0.32 
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The leads showed visible cuts and stretches. The coax wires were stretched along 
with cuts. Optical microscopy shows several areas the insulation had been degraded 
scratched or even cut and may affect the functionality of the devices. The lead damage 
modes and the percentage of each mode is summarized in table 4. 
Table 4 Lead Damage Mode Percentage, average damage and standard deviation 
  Damage Mode Damage percentage Average SD 
  
L
ea
d
 
P
ro
x
im
al
 
Surface Deformation 0.00% 0 0 
Pitting 0.00% 0 0 
Insulation Defect 12.82% 4.13 3.31 
Scratching 2.29% 1.39 0.69 
Burnishing 0.17% 0.67 0 
Abrasion 10.10% 2.44 1.44 
Coil Damage 0.34% 0.61 0.41 
Delamination 0.00% 0 0 
Discoloration 9.34% 2.33 1.68 
M
id
d
le
 
Surface Deformation 0.93% 2.68 0.12 
Pitting 0.00% 0 0 
Insulation Defect 28.52% 5.12 3.67 
Scratching 0.93% 1.09 0.57 
Burnishing 0.00% 0 0 
Abrasion 5.09% 2.37 1.42 
Coil Damage 12.05% 2.62 1.59 
Delamination 0.00% 0 0 
Discoloration 17.40% 2.49 1.54 
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Previous efforts from literature showed that electrical tests, optical microscopy and 
SEM [71] were performed on the lead. The work was presented to investigate for coil 
damage in 49 leads from one manufacturer. Additionally, Wiggins et al. [8] used optical 
microscopy, SEM and FTIR to determine the chemical degradation on the inner and outer 
insulation. This is a key feature of learning the residual properties of the leads and its 
insulation. They did their investigation about the biodegradation of the PU insulation of 7 
leads. In addition, Hauser et al. investigated the lead failure in one lead type [66]. 
Additionally, Mehta et al. [82] performed clinical evaluation of 132 randomized patients 
for four years to identify the complication of leads. This study [82] showed the same results 
as current work that the ICD leads are more vulnerable than pacing leads in insulation 
breakdown. 39 out of 132 ICD leads experienced inappropriate shock due to insulation 
breakdown [82]. On the other hand, our research showed 4 out of 21 ICD leads experiences 
insulation breakdown. Furthermore, Kron et al. used data from 539 patients for 4 years, 
and it showed that 2.8% of the leads fractured. Fortescue et al [72] collected data from one 
pediatric center during 1980-2002. A total of 1007 leads were implanted in 497 patients. 
Lead failure occurred in 155 leads 15%, and the patients who experienced multiple failures 
were 28%. They found the insulation defect percentage was 32.2% of the failed leads. In 
general, the investigation in this paper was significant due to the variation of the devices 
involved. It involved 65 cardiac devices and 136 leads from different manufacturers. Visual 
inspection, optical microscope inspection and electrical tests were performed to determine 
the damage modes for these devices. 
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Sensitivity metric equation was created from the data that were generated during 
this investigation from the devices. The goal was to mathematically model the sensitivity 
for any given time. A principal component analysis was performed for the acquired data to 
isolate those parameters that are the most important to create the sensitivity metric 
expression (S). It was noticed that as the voltage increased the pulse width decreased and 
vice-versa. Therefore, sensitivity function parameters (F) were defined in terms of voltage, 
(F1) and pulse width (F2) as reciprocal, (1/F2). It is important to note that if the voltage 
doubled, then the energy usage can be higher. Lastly, the time was a crucial component 
and by far the most important. 
𝑆 = 𝐹1
𝐹3 + 𝐹4
𝐹2
 
F1 is the voltage in millivolts, F2 is the pulse width in milliseconds, F3 is the in 
ohms, and lastly is F4 the current in milli-amperes. The interrogation of the devices leads 
to numerous discoveries, and the relation between sensitivity setting, pulse width and 
impedance can be revealed through the obtained reports. Sensitivity plot generated using 
MATLAB R2017a, that contained impedance, pulse width, and sensitivity setting as shown 
in Fig.42. This plot shows that with low impedance and high pulse width, the sensitivity is 
low. However, the impedance increases the sensitivity and pulse width, this scenario 
depletes the battery earlier than estimated. Sensitivity plot help physicians to choose 
appropriate parameters that can help in patient therapy. From Fig.42 one can set the 
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sensitivity voltage according to either the sensing test or depending on the figure generated 
and can compare the normal impedance to the corresponding voltage and pulse width. 
 
Figure 42 Sensitivity Plot 
3.5 CONCLUSION 
The devices used in this investigation were received from The Wright State Anatomical 
Gift Program. These devices were extracted posthumously and ranged from 3 months to 
192 months of in-vivo exposure. It can be inferred that the pulse generator cases had mainly 
scratches that were shallow, narrow and could not have affected the functionality of the 
devices. The discoloration on the cases was caused by the growth of organic material from 
the body or due to the exposition to fluids (alcohol, bleach, dimethyl formaldehyde etc.) 
used in the sterilization process of the devices after their retrieval. However, the 
discoloration could not have affected the functionality of the devices. In addition, the 
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investigation showed that the anterior side was more exposed to damage than the posterior 
side. The leads, which consist of the inner coil, outer coil and the insulation around the 
coils, had visible insulation defect, stretches, and coil damages that caused different types 
of failures and could have affected the functionality of the devices. However, these 
damages may have happened during the extraction/pulling of the devices or during the 
replacement of the leads not during the in vivo usage. In general, Medtronic leads showed 
significant resistance to different damage modes when compared to Boston Scientific and 
St. Jude medical, and the middle part was more exposed to damage than the proximal part. 
A damage equations were developed to determine the percentage damage for each mode. 
A Failure types quantitative assessment was developed for different failure types. Then, 
monte carlo simulation was performed to predict the failure probability of different types 
of leads failures. The output data for failure types were plotted in terms of actual values 
versus predicted values using JMP software. Finally, sensitivity plot was generated using 
Matlab to help physicians in understanding how the pulse width, impedance, and sensitivity 
setting are related.  
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CHAPTER 4 RESIDUAL PROPERTIES OF LEAD  
 
4.1 INTRODUCTION 
5076 CapSureFix Novus MRI SureScan Lead is multi-length, active fixation, bipolar, 
coaxial design lead. The insulation is achieved by silicone (MED-4719) as an outer 
insulator and as an insulator between the two coils (Medtronic, Minneapolis, MN, USA). 
This lead received FDA approval in 2000 [67].  
Silicone rubber was used during the 1960’s for the first time in the cardiac devices 
as an insulator for leads. It is biocompatible and biostable. However, it can tear easily at 
the same time possesses a high coefficient of friction. The silicon rubber also has tendency 
to creep, which leads to insulation necking at the area of sustained stresses [73]. Silicon 
was modified to overcome abrasion, tear and creep with higher tensile strength and 
abrasion resistance. These include high-performance (HP) silicone, extra-tear-resistant 
(ETR) silicone, and Novus (Med-4719, Nusil Technologies, Carpinteria, Calif), produced 
by hybridizing HP and MDX4 silicone [74]. 5076 CapSureFix Novus MRI SureScan Lead 
uses Novus (Med-4719) as an insulator [67].  
Residual properties of leads are found in the literature sparingly. Few studies 
presented how residual properties deteriorating with in-vivo exposure [10, 11, 60, 75]. For 
instance, Helguera et al. [75], studied 992 silicon leads of 26 (2.6%) predicted to fail after 
a period of 5-10 years, while 10 (1.0%) leads were actually failed after that period. Other 
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feature reported by Chan et al. [10], Starck et al. [11], and Wilkoff et al. [60] is discussed 
in chapter two. 
4.2 METHOD 
Twenty 5076 CapSureFix Novus MRI SureScan pacing leads were used in the experiment. 
This lead is 52 cm active fixation, bipolar, coaxial design, with silicone (MED-4719) as an 
outer insulator and as an insulator between the two coils (Medtronic, Minneapolis, MN, 
USA). Two of the leads were provided by Medtronic. The rest of the leads were received 
from the Wright State University Anatomical Gift Program. In vivo implantation duration 
was different for each lead with an average of 62±55 months. Test Resources Q series 
system was used to perform the tensile test. Fig.43 demonstrates the test procedure 
including the samples' length before and after the test, the fixture, and the cross-section of 
the sample under the microscope showing the coils and two insulators. Complying to 
ASTM Standard D 1708-02a [76] (Standard Test Method for Tensile Properties of Plastic 
by Use of Microtensile Specimens) and ASTM Standard D 412-06a [77] (Standard Test 
Methods for Vulcanized Rubber and Thermoplastic Elastomers-Tension). The length of 
the samples were fixed to 38mm for all tested leads, 8mm in the grip and 22mm between 
the grips. The leads were tested with the coil inside the insulation. The lead was fixed in 
the grips by sand paper to avoid slippering. The tensile test was performed by applying 
specific loads on the samples, and the corresponding displacement measured. The tensile 
test was repeated at least five times and the average of the results was calculated. First, the 
diameter was measured for each specimen at three locations and the average diameter was 
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calculated. A gage of 22 mm length was used for all the specimens. Also, all leads were 
examined under the optical microscope to investigate the damage before and after the tests 
as shown in Fig.44. The tensile test was applied at a rate of 1 mm/sec, and the body of the 
lead was observed for extension. In addition, load to failure, elongation to failure, 
percentage elongation at 5N, ultimate tensile strength, and modulus of elasticity were 
calculated after the lead insulation separated. Finally, the equivalent data were compared 
with respect to the in-vivo exposure in years. 
Table 5 List of the Leads used with their SN, implant date and estimated retrieval date 
# Lead Type SN Insulation Implant Date Estimated explant 
date 
IN-VIVO Duration 
1 5076 PJN3644744 Silicon NA NA New Lead 
2 5076 PJN2329144 Silicon November/2010 January/2017 74 months 
3 5076 PJN2815001 Silicon September/2012 March/2018 66 Months 
4 5076 PJN2814368 Silicon September/2012 March/2018 66 Months 
5 5076 PJN3973695 Silicon January/2016 March/2018 26 Months 
6 5076 PJN2621551 Silicon October/2011 December/2017 73 Months 
7 5076 PJN4619372 Silicon June/2017 September/2017 3 MONTHS 
8 5076 PJN2206204 Silicon June/2010 September/2011 15 Months 
9 5076 PJN2213707 Silicon June/2010 September/2011 15 Months 
10 5076 PJN3633312 Silicon May/2015 December/2016 18 MONTHS 
11 5076 PJN3722285 Silicon May/2015 December/2016 18 MONTHS 
12 5076 PJN4057165 Silicon March/2016 August/2016 6 MONTHS 
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Figure 43 A) Specimen measurement, (B) Cross-section of the lead, (C) During the test, (D) At the break point, (E) After 
deformation 
A B C D E
13 5076 PJN4070036 Silicon March/2016 August/2016 6 MONTHS 
14 5076 PJN4043721 Silicon March/2016 November/2016 8 MONTHS 
15 5076 PJN4060504 Silicon March/2016 November/2016 8 MONTHS 
16 5076 PJN3935482 Silicon November/2015 January/2017 13 MONTHS 
17 5076 PJN2412482 Silicon December/2011 October/2017 71 MONTHS 
18 5076 PJN625058V Silicon August/2004 May/2012 94 Months 
19 5076 PJN641773V Silicon August/2004 May/2012 94 Months 
20 5076 PJN1086898 Silicon December/2006 December/2017 132 MONTHS 
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Figure 44 Microscopic inspection for the lead before and after tensile test 
 
4.3 RESULTS 
4.3.1 Load to Failure 
The load to failure of the new lead was 26.477N ± 3.4 N. However, this value had 
deteriorated to 24.918N ± 0.55 N after 6 months of in-vivo implantation. The maximum 
load had decreased slightly after 9 months to reach 24.7543N±0.2N. Then the load to 
failure declined to 18.012N ± 5.33 N after 18 months of implantation (P-value <0.0001) 
and continued to decline to 13.3682N ±0.345N after 132 months of in-vivo exposure, as 
shown in Fig. 45. 
76 
 
 
Figure 45 Representative Load to Failure vs in-vivo months plot of 5076 CapSureFix Novus MRI SureScan pacing leads 
 
A mathematical model developed to predict the maximum load with respect to the number 
of in-vivo months: 
𝐿𝑜𝑎𝑑 𝑡𝑜 𝐹𝑎𝑖𝑙𝑢𝑟𝑒 =  −0.0767𝑥 +  23.57 
Where τ represents number of months. 
 Statistical analysis performed for the maximum load and found that there is a 
significant difference in maximum load after 18 months (P-value <0.0001), this difference 
can be represented by the drop of the load from 24.343N to 18.3566N. Student’s T test 
used to compare between all the data in term of number of in-vivo months(α=0.01), and 
the connecting letters report was generated as shown in table 6. 
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Table 6 Connecting letter report for load to failure statistical analysis. Levels not connected by same letter are 
significantly different. 
Connecting Letters Report 
Months   Mean 
0 A   25.5091 
6 A   24.9183 
9 A   24.6585 
15 A   24.3435 
18   B 18.3566 
26   B 16.9615 
94   B 14.7436 
124   B 14.3256 
132   B 13.3192 
 
4.3.2 Elongation to Failure 
In addition, similar outcomes were found for the elongation to failure, as it declined from 
173.2255 % ± 40.484% for the new lead to 140.761% ± 8.603% after 8 months of 
implantation. The percentage elongation dropped to 110.39% ± 2.25% after 15 months and 
continued to drop to 106.96% ± 5.4% after 94 months as shown in Fig.46. A mathematical 
model developed to predict the percentage elongation with respect to the number of in-vivo 
months: 
𝐸𝑙𝑜𝑛𝑔𝑎𝑡𝑖𝑜𝑛 𝑡𝑜 𝐹𝑎𝑖𝑙𝑢𝑟𝑒 =  −0.3433𝑥 +  138.63 
Where τ represents the number of months. 
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Figure 46 Representative Percentage Elongation vs in-vivo months plot of 5076 CapSureFix Novus MRI SureScan pacing 
leads 
 
Statistical analysis performed for the elongation to failure. It was found there is a 
significant difference in elongation to failure after 94 months (P-value<0.0001), this 
difference can be represented by the drop of the elongation to failure from 132.2695 % to 
111.507%. Then Student’s T test used to compare between all the data in term of number 
of in-vivo months, and the connecting letters report generated as shown in table 7. 
Table 7 Connecting letter report for percentage elongation statistical analysis. Levels not connected by same letter are 
significantly different 
Connecting Letters Report 
Months   Mean 
0 A     180.696 
6   B   150.146 
8   B   145.361 
13   B C 132.27 
26   B C 120.848 
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66   B C 114.795 
94     C 111.507 
18     C 110.55 
15     C 110.391 
124     C 109.934 
132     C 106.966 
71     C 106.1 
 
4.3.3 Percentage Elongation at 5N force 
The percentage elongation was investigated in this study for 5 N force, as literature showed 
that the maximum load that can be applied to the lead in-vivo is within the range of 5 N 
[83]. Percentage elongation at 5N force was similar to percentage elongation during load 
to failure and resulting percentage elongation after tests. It showed there is a significant 
difference after 66 months of in-vivo exposure when compared to new lead (P-
value=0.0037), as shown in table 8. A mathematical model developed to predict the 5N 
force percentage elongation with respect to the number of in-vivo months: 
5𝑁 𝐹𝑜𝑟𝑐𝑒 𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐸𝑙𝑜𝑛𝑔𝑎𝑡𝑖𝑜𝑛 = −0.1205𝑥 +  21.905 
Where τ represents the number of months. 
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Figure 47 Representative Percentage Elongation at 5N vs in-vivo months plot of 5076 CapSureFix Novus MRI SureScan 
pacing leads 
 
Table 8 Connecting letter report for 5N percentage elongation statistical analysis. Levels not connected by same letter 
are significantly different 
Connecting Letters Report 
Months 
 
Mean 
0 A 
  
20.73325 
8 A 
  
20.34955 
15 A 
  
19.1 
66 
 
B 
 
13.79487 
71 
 
B C 9.32 
94 
  
C 7.295 
132 
  
C 7.032 
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4.3.4 Ultimate Tensile Strength  
Additionally, the ultimate tensile strength (UTS) was found to be 8.762 MPa ± 0.623 MPa 
for the new leads. The UTS has slightly decreased to 8.095 MPa ± 2.448 MPa after 6 
months of implantation and continues decreasing until 73 months with significant 
decrement (P-value =0.0339) compared to the new lead. A mathematical model developed 
to predict ultimate tensile strength with respect to the number of in-vivo months: 
𝑈𝑇𝑆 =  −0.0331𝜏 +  8.4992 
Where τ represents the number of months. 
 
Figure 48 Representative Ultimate Tensile Strength vs in-vivo months plot of 5076 CapSureFix Novus MRI SureScan 
pacing leads 
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Table 9 Connecting letter report for Ultimate tensile strength statistical analysis. Levels not connected by same letter 
are significantly different 
Connecting Letters Report 
Months           Mean 
0 A         8.7615 
6 A B       8.09478 
9 A B       7.96449 
15 A B       7.91193 
66 A B       7.39405 
18 A B       7.03019 
73   B C     6.44735 
74   B C D   6.18506 
94     C D E 5.07465 
124       D E 4.86972 
101     C D E 4.78037 
132         E 3.9767 
 
4.3.5 Modulus of Elasticity 
Finally, the modulus of elasticity is calculated and statistically analyzed. Modulus of 
elasticity was directly proportional to the number of in-vivo exposure as shown in Fig.44. 
The statistical analysis showed a significant increase in modulus of elasticity after 73 
months (P-value =0.0051). A mathematical model developed to predict the modulus of 
elasticity with respect to the number of in-vivo months: 
𝐸 =  0.1077𝜏 +  9.4292 
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Where τ represents the number of months. 
The residual properties of leads tested during this research are summarized in table 
11. Duration of in-vivo environment, load to failure, elongation to failure, percentage 
elongation at 5N force, ultimate tensile strength, and modulus of elasticity presented along 
with where the insulation broke. 
 
Figure 49 Representative Modulus of Elasticity vs in-vivo months plot of 5076 CapSureFix Novus MRI SureScan pacing 
lead 
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Table 10 Connecting letter report for Modulus of Elasticity statistical analysis. Levels not connected by same letter are 
significantly different 
Connecting Letters Report 
Months             Mean 
132 A           21.7643 
101 A B         20.3861 
94 A B C       19.1738 
71 A B C D E   19.0779 
73 A B C D     17.5802 
66 A B C D E F 16.751 
18       D E F 11.7585 
15     C D E F 11.4847 
13   B C D E F 10.8521 
9     C D E F 10.7684 
8         E F 10.0472 
6       D E F 9.56144 
0           F 7.45253 
 
 
Table 11 Residual properties of the tested leads with corresponding area of insulation break 
In-vivo 
Duration 
Load to 
failure 
(N) 
Max. 
Elongation 
(%) 
5N 
Elongation 
(%) 
UTS 
(MPa) 
Modulus of 
Elasticity 
(MPa) 
No. of 
samples 
tested 
Area of 
Insulation 
break 
New Lead 26.477 186.684 20.733 8.761 7.453 8 Middle  
6 Months 24.918 150.365 20.711 8.095 9.561 7 Middle  
9 Months 24.754 131.884 20.855 7.964 10.768 6 Middle  
85 
 
15 Months 24.843 110.391 24.394 7.912 11.485 7 Middle  
18 Months 18.012 107.815 19.650 7.566 11.758 7 Middle  
26 Months 16.962 114.045 19.550 5.653 9.419 6 Middle  
66 Months 16.826 114.795 13.794 7.394 16.751 5 Lower 
71 Months 16.976 106.100 9.320 6.447 19.078 8 Middle 
94 Months 16.334 105.893 7.240 5.075 19.174 5 Middle 
124 Months 15.291 102.673 9.023 4.780 20.386 5 Lower  
132 Months 13.368 101.236 8.060 3.977 21.764 4 Middle  
 
 
4.4 DISCUSSION 
Understanding the deterioration of the residual properties and the performance of the leads 
after implantation is very important in order to improve lead materials and durability inside 
the human body. In this study, an investigation of the residual properties of the Medtronic 
5076 CapSureFix Novus MRI SureScan lead was performed with respect to in vivo 
implantation duration. The results showed that the load to failure, UTS, and elongation 
dropped significantly after 18, 73 and 94 months of in-vivo exposure respectively. This is 
due to the effect of internal body environment on the insulator (silicone (MED-4719)). 
Longer exposure does not lower the mechanical properties at the same rate as it does during 
the first 18 months of exposure. Finally, a significant drop in the residual properties 
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occurred after 73 months of implantation, which is probably as a result of creep, abrasion, 
tear and environmental interaction [74]. 
On the other hand, modulus of elasticity showed an increase as the number of in-
vivo months increased and reaches maximum elasticity at 132 months of in-vivo 
environment. This due to the reaction between blood and the lead, which may increase the 
temperature around the lead. Since silicone rubber has high coefficient of friction, its 
temperature increases easily due the chemical reaction that occurs around the surface of 
lead [75]. 
All in-vivo years are plotted individually, and a comparison was made between 
experimental results and predicted results, as shown in Fig. 50. All prediction equation are 
summarized in table 12. 
The sensitivity plot (Fig.51) shows a relation between load to failure, elongation, 
and in-vivo exposure in years. And it can be inferred that both load to failure and elongation 
decrease with the increase of in-vivo exposure. Fig.52 shows a mathematical relationship 
of the measured parameters with each other. A sensitivity plot indicates with the increase 
in in-vivo exposure the modulus of elasticity increases, and the ultimate tensile strength 
decreases and vice versa. 
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Figure 50 Representative Load vs extension plot for different In Vivo Implantation Durations 
 
Table 12 Prediction Equations for each in-vivo duration, where x is the lead extension in mm 
In-vivo Duration Prediction equation 
R-
squared 
New Lead Pred.= -4E-07x6 + 4E-05x5 - 0.0018x4 + 0.039x3 - 0.4912x2 + 4.0021x 0.996 
6 months Pred.= -4E-06x6 + 0.0003x5 - 0.0082x4 + 0.118x3 - 0.9629x2 + 5.2306x 0.9934 
9 months Pred.= -1E-06x6 + 7E-05x5 - 0.0021x4 + 0.0315x3 - 0.3193x2 + 3.1186x 0.9932 
15 months Pred.= -2E-06x6 + 0.0001x5 - 0.0034x4 + 0.0472x3 - 0.4403x2 + 3.6648x 0.9954 
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18 months 
Pred.= -2E-06x6 + 9E-05x5 - 0.0017x4 + 0.0157x3 - 0.1707x2 + 2.7002x 
+ 1 
0.9923 
26 months Pred.= -5E-07x6 + 4E-05x5 - 0.0012x4 + 0.0171x3 - 0.1447x2 + 1.5803x 0.9854 
71 months Pred.= -6E-06x6 + 0.0004x5 - 0.0102x4 + 0.1289x3 - 0.9429x2 + 4.5987x 0.9869 
124 months Pred.= -6E-07x6 + 5E-05x5 - 0.0017x4 + 0.0247x3 - 0.1883x2 + 1.4856x 0.9799 
132 months Pred.= -1E-05x6 + 0.0005x5 - 0.0076x4 + 0.068x3 - 0.6386x2 + 4.3304x 0.9844 
 
 
 
Figure 51 Sensitivity Plot representing Max. load vs Elongation vs in-vivo years 
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Figure 52 Sensitivity Plot representing Modulus of elasticity vs Ultimate tensile strength vs in-vivo months 
 
 
Figure 53 Representative Load vs extension plot of 5076 CapSureFix Novus MRI SureScan pacing leads 
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4.5 CONCLUSION 
Medtronic 5076 CapSureFix Novus MRI SureScan Lead is still used as the main lead in 
their systems, and further investigations are required to fully understand it’s in-vivo 
behavior. The materials used in the insulation are subjected to failure due to creep and 
wear. Load to failure showed a significant decrease after 18 months of in-vivo exposure 
(P-value =0.0008). Percentage elongation showed a significant decrease after 94 months 
of in-vivo exposure (P-value <0.0001). Ultimate tensile strength showed significant 
decrease after 73 months of in-vivo exposure (P-value =0.0339) and percentage elongation 
at 5N force showed significant decrease after 66 months of in-vivo exposure (P-value 
=0.0037). On the other hand, modulus of elasticity was directly proportional with the in-
vivo exposure time and showed significant increase (P-value =0.0051) after 73 months. 
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CHAPTER 5: CONCLUSION AND FUTURE 
RECOMMENTDATIONS 
 
The devices used in this investigation were received from The Wright State Anatomical 
Gift Program. These devices were extracted posthumously and ranged from 3 months to 
192 months of in-vivo exposure. It can be inferred that the pulse generator cases had mainly 
scratches that were shallow, narrow and could not have affected the functionality of the 
devices. The discoloration on the cases was caused by the growth of organic material from 
the body or due to the exposition to fluids (alcohol, bleach, dimethyl formaldehyde etc.) 
used in the sterilization process of the devices after their retrieval. However, the 
discoloration could not have affected the functionality of the devices. In addition, the 
investigation showed that the anterior side was more exposed to damage than the posterior 
side.  
The leads, which consist of the inner coil, outer coil and the insulation around the 
coils, had visible insulation defect, stretches, and coil damages that caused different types 
of failures and could have affected the functionality of the devices. However, these 
damages may have happened during the extraction/pulling of the devices or during the 
replacement of the leads not during the in vivo usage. In general, Medtronic leads showed 
significant resistance to different damage modes when compared to Boston Scientific and 
St. Jude medical, and the middle part was more exposed to damage than the proximal part. 
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Damage summation equations were developed to determine the total damage for 
pulse generators and leads. A quantitative scoring assessment was performed for pulse 
generators and leads. Linear summation of damage modes described the total damage on 
both PG and leads. Using the survival probability of the devices from interrogation data 
and damage scores. Monte carlo simulation was performed to predict the failure probability 
associated risks. The output data for failure types were plotted in terms of actual values 
versus predicted values using JMP software.  
Medtronic 5076 CapSureFix Novus MRI SureScan Lead is still used as the main 
lead in their systems, and further investigations are required to fully understand its in-vivo 
behavior. The materials used in the insulation are subjected to failure due to creep and 
wear. Load to failure showed a significant decrease after 18 months of in-vivo exposure 
(P-value =0.0008). Percentage elongation showed a significant decrease after 94 months 
of in-vivo exposure (P-value<0.0001). Ultimate tensile strength showed significant 
decrease after 73 months of in-vivo exposure (P-value=0.0339) and percentage elongation 
at 5N force showed significant decrease after 66 months of in-vivo exposure (P-value 
=0.0037). On the other hand, modulus of elasticity was directly proportional with the in-
vivo exposure time and showed significant increase (P-value =0.0051) after 73 months. 
This thesis provides valuable data that could assist in the design of novel cardiac devices 
and enhance durability. 
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APPENDIX I LIST OF DEVICES 
 
Table 13 Devices Serial numbers, model, type, manufacturer, and status 
# Model Type SN Manufacturer Status 
1 EnPulse DDDR Pacemaker DR PNB453720H MDT Not Active 
2 EnPulse DDDR Pacemaker DR PN8474286H MDT Active 
3 EnPulse DDDR Pacemaker DR PNB462475H MDT Not Active 
4 EnPulse DDDR Pacemaker DR PWU411542H MDT Not Active 
5 REAVEAL XT Loop Recorder RAB508196H MDT Not Active 
6 ADVISA DR MRI Pacemaker DR PAY287174H MDT Active 
7 ADVISA DR MRI Pacemaker DR PAY354210H MDT Active 
8 ADAPTA DDDR Pacemaker DR PWB261682H MDT Not Active 
9 ADAPTA DDDR Pacemaker DR NWB540331H MDT Active 
10 SENSIA SSIR Pacemaker SR NWR205596H MDT Not Active 
11 SENSIA SSIR Pacemaker SR NWE205745H MDT Active 
12 SENSIA DDDR Pacemaker DR NWL230140H MDT Active 
13 SENSIA DDDR Pacemaker DR NWL230175H MDT Not Active 
14 REVO MRI DDDR Pacemaker DR PTN264280H MDT Active 
15 SECURA DR ICD DR PUG205844H MDT Not Active 
16 CONCERTO II CRT-D CRT-D PZA204401H MDT Active 
17 VIVA XT CRT-D CRT-D BLF234921H MDT Active 
18 VIVA XT CRT-D CRT-D BLF221559H MDT Not Active 
19 CONSULTA CRT-D CRT-D PUD220940H MDT Not Active 
20 EVERA MRI XT DR ICD DR PFZ201839H MDT Active 
21 ENRHYTHM DDDR Pacemaker DR PNP488829H MDT Active 
22 ENRHYTHM DDDR Pacemaker DR PNP422130H MDT Active 
23 ADAPTA DDDR Pacemaker DR NWB424054H MDT Active 
24 ADAPTA DDDR Pacemaker DR NWB201749H MDT Not Active 
25 ADAPTA DDDR Pacemaker DR PWB268153H MDT Not Active 
26 ADAPTA DDDR Pacemaker DR NWB528525H MDT Not Active 
27 KAPPA DDDR Pacemaker DR PGU402621H MDT Not Active 
28 SIGMA S DR Pacemaker DR PJD194315H MDT Not Active 
29 SYNCRA CRT-P CRT-P PZX603451S MDT Active 
30 CONSULTA CRT-D CRT-D PUD227370H MDT Not Active 
31 ENTRUST DR ICD DR PNR425289H MDT Not Active 
32 CONSULTA CRT-D CRT-D PUD205493H MDT Not Active 
33 MAXIMO II DR ICD DR PZM201316H MDT Not Active 
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34 Adapta DR Pacemaker DR NWB217705H MDT Active 
35 Adapta DR Pacemaker DR NWB525560H MDT Active 
36 Adapta DR Pacemaker DR NWB558100H MDT Active 
37 Adapta DR Pacemaker DR BWB297611H MDT Not Active 
38 Advisa DR MRI SureScan Pacemaker DR PAY338992H MDT Active 
39 Claria MRI SureScan CRT-D RPT200404H MDT Active 
40 Viva XT CRT-D CRT-D BLF225581H MDT Active 
41 Viva XT CRT-P CRT-P PVZ602494S MDT Active 
42 Consulta CRT-P CRT-P PVX625114S MDT Active 
43 Consulta CRT-P CRT-P PVX621568S MDT Active 
44 Evera XT VR ICD-VR BWI215647H MDT Not Active 
45 Evera XT VR ICD-VR BWI214708H MDT Active 
46 Protecta XT ICD DR PSA212334H MDT Active 
47 Evera XT DR ICD DR BWB207000H MDT Active 
48 INSIGNIA PLUS SSIR Pacemaker SR 111673 BSC Not Active 
49 INSIGNIA 1 PLUS DDDR Pacemaker DR 952466 BSC Active 
50 ESSENTIO DDDR Pacemaker DR 733737 BSC Active 
51 COGNIS 100-D CRT-D 202270 BSC Active 
52 ENERDEN ICD ICD-DR 111850 BSC Active 
53 VITALITY DS ICD-DR 124431 BSC Active 
54 VITALITY HE ICD-DR 200093 BSC Active 
55 ALTRUA 60 DDDR Pacemaker DR 952367 BSC Active 
56 ADVANTIO DDDR Pacemaker DR 118816 BSC Active 
57 COGNIS 100-D CRT-D 485497 BSC Active 
58 Teligen 100 ICD-DR 250119 BSC Not Active 
59 Advantio  Pacemaker DR 121699 BSC Active 
60 Altura 60 DR Pacemaker DR 843287 BSC Active 
61 Accolade MRI Pacemaker SR 739063 BSC Active 
62 Ingenio VR Pacemaker SR 116716 BSC Active 
63 Fortify Assura ICD DR 7230932 St. Jude Active 
64 ZEPHYR XL DR Pacemaker DR 1294876 St. Jude Not Active 
65 PARAGON DDDC Pacemaker DR 34400 St. Jude Not Active 
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APPENDIX II TOTAL DAMAGE SCORE EQUATIONS 
 
Pulse Generator Total Damage Score 
𝑃𝑢𝑙𝑠𝑒 𝐺𝑒𝑛𝑒𝑟𝑎𝑡𝑜𝑟 𝑇𝑜𝑡𝑎𝑙 𝐷𝑎𝑚𝑎𝑔𝑒 𝑆𝑐𝑜𝑟𝑒 = ∑∑ 
𝑛
𝑦=1
2
𝑥=1
𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒𝑥𝑦 
=∑ 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝐷𝑒𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
2
𝑥=1
 
+∑𝐷𝑖𝑠𝑐𝑜𝑙𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
2
𝑥=1
 
+∑ 𝑆𝑐𝑟𝑎𝑡𝑐ℎ𝑖𝑛𝑔 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
2
𝑥=1
 
+∑𝐵𝑢𝑟𝑛𝑖𝑠ℎ𝑖𝑛𝑔 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
2
𝑥=1
 
+∑𝑃𝑖𝑡𝑡𝑖𝑛𝑔 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
2
𝑥=1
 
+∑𝐴𝑏𝑟𝑎𝑠𝑖𝑜𝑛 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
2
𝑥=1
 
 
Where x=1 through 2 represents the anterior and posterior part of the pulse generator. 
 
 
Lead Total Damage Score 
𝐿𝑒𝑎𝑑 𝑇𝑜𝑡𝑎𝑙 𝐷𝑎𝑚𝑎𝑔𝑒 𝑆𝑐𝑜𝑟𝑒 = ∑∑  
𝑛
𝑦=1
2
𝑥=1
𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒𝑥𝑦 
∑ 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝐷𝑒𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
 
+∑𝐷𝑖𝑠𝑐𝑜𝑙𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
 
+∑ 𝑆𝑐𝑟𝑎𝑡𝑐ℎ𝑖𝑛𝑔 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
 
+∑𝐵𝑢𝑟𝑛𝑖𝑠ℎ𝑖𝑛𝑔 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
 
∑ 𝐼𝑛𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐷𝑒𝑓𝑒𝑐𝑡 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
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+∑𝐴𝑏𝑟𝑎𝑠𝑖𝑜𝑛 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
 
+∑𝐶𝑜𝑖𝑙 𝐷𝑎𝑚𝑎𝑔𝑒 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
 
+∑𝐷𝑒𝑙𝑎𝑚𝑖𝑛𝑎𝑡𝑖𝑜𝑛  𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
 
+∑𝑃𝑖𝑡𝑡𝑖𝑛𝑔 𝑆𝑒𝑣𝑒𝑟𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒
𝑥
3
𝑥=1
 
 
 
 
Where x=1 through 2 represents each part of the lead. 
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APPENDIX III PULSE GENERATOR 
 
 
Figure 54 ADAPTA (PWB297611H 
111 
 
 
 
Figure 55 Adapta DR (NWB528525H) 
 
Figure 56 Adapta DR (PWB268153H) 
 
Figure 57 Advisa DR MRI (PAY287174H) 
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Figure 58 Altrua 60 (843287) 
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Figure 59 Altrua 60 DR (952367) 
 
Figure 60 Entrust (PNR425289H) 
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Figure 61 Evera XT VR (BWI214708H) 
 
Figure 62 Evera XT VR (BWI215647H) 
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Figure 63 Evera XT DR (BWB207000H) 
 
116 
 
 
Figure 64 Maximo II (PZM201316H) 
 
Figure 65 Protecta XT VR (PSA212334H) 
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Figure 66 Zephyr XL DR (1294876) 
 
Figure 67 Viva XT CRT-D (BLF225581H)  
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APPENDIX IV LEAD 
 
 
Figure 68 INGEVITY Pacing Lead (786132) 
 
Figure 69 CapSureFix Pacing Lead (PJN1069523) 
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Figure 70 CapSure SP Pacing Lead (LAV070864V) left, Crystalline Pacing Lead (VMR021968V) right 
 
Figure 71 CapSureFix Pacing Lead (PJN2528024) 
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Figure 72 CapSureFix Pacing Lead (PJN956553V)  
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Figure 73 6949 Sprint Fidelis ICD Lead (LFJ217747) 
 
Figure 74 INGEVITY Pacing Lead 
 
Figure 75 6947 Sprint Quattro Secure (TDG275450V) 
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Figure 76 4194 Attain OTW Left-Heart Pacing (LFG204735V) 
 
Figure 77 Tendril™ SDX Pacing Lead (DC23385) 
 
Figure 78 CapSure SP Pacing Lead (LAV091616V) 
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APPENDIX V MATLAB CODE 
 
function createfigure(ZData1, YData1, XData1, VertexNormals1, XData2, YData2, 
ZData2) 
%CREATEFIGURE(ZDATA1, YDATA1, XDATA1, VERTEXNORMALS1, XDATA2, YDATA2, ZDATA2) 
%  ZDATA1:  surface zdata 
%  YDATA1:  surface ydata 
%  XDATA1:  surface xdata 
%  VERTEXNORMALS1:  surface vertexnormals 
%  XDATA2:  line xdata 
%  YDATA2:  line ydata 
%  ZDATA2:  line zdata 
 
%  Auto-generated by MATLAB on 31-May-2018 19:56:07 
 
% Create figure 
figure1 = figure('Tag','Print CFTOOL to Figure',... 
    'Color',[0.941176470588235 0.941176470588235 0.941176470588235],... 
    'OuterPosition',[1 1 1536 467.2]); 
 
% Create axes 
axes1 = axes('Parent',figure1,'Tag','sftool surface axes'); 
hold(axes1,'on'); 
 
% Create surface 
surface('Parent',axes1,'ZData',ZData1,'YData',YData1,'XData',XData1,... 
    'DisplayName','untitled fit 1',... 
    'VertexNormals',VertexNormals1,... 
    'EdgeAlpha',0.3,... 
    'CData',ZData1); 
 
% Create line 
line(XData2,YData2,ZData2,'Parent',axes1,... 
    'DisplayName','Impedance vs. Sensitivity, PulseWidth',... 
    'MarkerFaceColor',[0 0 0],... 
    'MarkerEdgeColor',[0 0 0],... 
    'MarkerSize',3,... 
    'Marker','o',... 
    'LineStyle','none'); 
 
% Create xlabel 
xlabel('Sensitivity'); 
 
% Create zlabel 
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zlabel('Impedance'); 
 
% Create ylabel 
ylabel('PulseWidth'); 
 
% Uncomment the following line to preserve the X-limits of the axes 
% xlim(axes1,[0.035 5.865]); 
% Uncomment the following line to preserve the Y-limits of the axes 
% ylim(axes1,[0.265 1.035]); 
% Uncomment the following line to preserve the Z-limits of the axes 
% zlim(axes1,[293.75 981.25]); 
view(axes1,[-23.4200000000001 14]); 
box(axes1,'on'); 
grid(axes1,'on'); 
% Create colorbar 
colorbar('peer',axes1); 
 
Survival Probability for devices in general 
function [pd1,pd2] = createFit(BSC,MDT) 
%CREATEFIT    Create plot of datasets and fits 
%   [PD1,PD2] = CREATEFIT(BSC,MDT) 
%   Creates a plot, similar to the plot in the main distribution fitter 
%   window, using the data that you provide as input.  You can 
%   apply this function to the same data you used with dfittool 
%   or with different data.  You may want to edit the function to 
%   customize the code and this help message. 
% 
%   Number of datasets:  2 
%   Number of fits:  2 
% 
%   See also FITDIST. 
 
% This function was automatically generated on 09-Jul-2018 23:21:39 
 
% Output fitted probablility distributions: PD1,PD2 
 
% Data from dataset "BSC data": 
%    Y = BSC 
 
% Data from dataset "MDT data": 
%    Y = MDT 
 
% Force all inputs to be column vectors 
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BSC = BSC(:); 
MDT = MDT(:); 
 
% Prepare figure 
clf; 
hold on; 
LegHandles = []; LegText = {}; 
 
 
% --- Plot data originally in dataset "BSC data" 
[CdfY,CdfX] = ecdf(BSC,'Function','survivor');  % compute empirical function 
hLine = stairs(CdfX,CdfY,'Color',[0.333333 0 0.666667],'LineStyle','-', 
'LineWidth',1); 
xlabel('Data'); 
ylabel('Survivor function') 
LegHandles(end+1) = hLine; 
LegText{end+1} = 'BSC data'; 
 
% --- Plot data originally in dataset "MDT data" 
[CdfY,CdfX] = ecdf(MDT,'Function','survivor');  % compute empirical function 
hLine = stairs(CdfX,CdfY,'Color',[0.333333 0.666667 0],'LineStyle','-', 
'LineWidth',1); 
xlabel('Data'); 
ylabel('Survivor function') 
LegHandles(end+1) = hLine; 
LegText{end+1} = 'MDT data'; 
 
% Create grid where function will be computed 
XLim = get(gca,'XLim'); 
XLim = XLim + [-1 1] * 0.01 * diff(XLim); 
XGrid = linspace(XLim(1),XLim(2),100); 
 
 
% --- Create fit "fit 1" 
 
% Fit this distribution to get parameter values 
% To use parameter estimates from the original fit: 
%     pd1 = ProbDistUnivParam('normal',[ 2.904545454545, 1.993546405963]) 
pd1 = fitdist(BSC, 'normal'); 
% This fit does not appear on the plot 
 
% --- Create fit "fit 2" 
 
% Fit this distribution to get parameter values 
% To use parameter estimates from the original fit: 
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%     pd2 = ProbDistUnivParam('normal',[ 2.433333333333, 1.888042870899]) 
pd2 = fitdist(MDT, 'normal'); 
% This fit does not appear on the plot 
 
% Adjust figure 
box on; 
hold off; 
 
% Create legend from accumulated handles and labels 
hLegend = legend(LegHandles,LegText,'Orientation', 'vertical', 'FontSize', 9, 
'Location', 'northeast'); 
set(hLegend,'Interpreter','none'); 
 
Survival probability for Pacemakers 
function createfigure1(X1, Y1, X2, Y2) 
%CREATEFIGURE1(X1, Y1, X2, Y2) 
%  X1:  vector of x data 
%  Y1:  vector of y data 
%  X2:  vector of x data 
%  Y2:  vector of y data 
 
%  Auto-generated by MATLAB on 04-Feb-2019 20:16:19 
 
% Create figure 
figure1 = figure; 
 
% Create axes 
axes1 = axes('Parent',figure1,... 
    'ColorOrder',[1 0 0;0 0 1;0.666666666666667 0.333333333333333 
0;0.333333333333333 0.333333333333333 0.333333333333333;1 0 1;1 1 0;1 
0.666666666666667 0.333333333333333;0.666666666666667 0.666666666666667 
0.666666666666667;0.666666666666667 0.333333333333333 1;0 0.666666666666667 
0.333333333333333;0.666666666666667 0 0.333333333333333;1 0.333333333333333 
0.666666666666667;0 1 0;0.333333333333333 0.666666666666667 1;0.666666666666667 
1 0.333333333333333;0.333333333333333 0 0.666666666666667;0 0.333333333333333 
0.666666666666667;0.333333333333333 1 0.666666666666667;0 0 0;0.333333333333333 
0.666666666666667 0;0.333333333333333 0 0.666666666666667],... 
    'Tag','main'); 
hold(axes1,'on'); 
 
% Create plot 
plot(X1,Y1,'DisplayName','BSC Pacemaker (n=8)','Tag','dfdata',... 
    'MarkerIndices',[1 2 3 4 5 6 7 8 9 10 11 12 13 14],... 
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    'LineWidth',1,... 
    'Color',[0 0 1]); 
 
% Create plot 
plot(X2,Y2,'ZDataSource','','DisplayName','MDT Pacemaker (n=23)',... 
    'Tag','dfdata',... 
    'LineWidth',1,... 
    'Color',[0 0 0]); 
 
% Create xlabel 
xlabel('Data'); 
 
% Create ylabel 
ylabel('Survivor function'); 
 
% Uncomment the following line to preserve the X-limits of the axes 
% xlim(axes1,[0.0675 8.4825]); 
% Uncomment the following line to preserve the Y-limits of the axes 
% ylim(axes1,[0 1]); 
% Uncomment the following line to preserve the Z-limits of the axes 
% zlim(axes1,[0 1]); 
box(axes1,'on'); 
% Set the remaining axes properties 
set(axes1,'OuterPosition',[-0.00178571428571429 -0.00238095238095238 1 1]); 
% Create legend 
legend1 = legend(axes1,'show'); 
set(legend1,'Interpreter','none'); 
 
 
Survival probability for leads in general 
function createfigure2(X1, Y1, X2, Y2, X3, Y3) 
%CREATEFIGURE2(X1, Y1, X2, Y2, X3, Y3) 
%  X1:  vector of x data 
%  Y1:  vector of y data 
%  X2:  vector of x data 
%  Y2:  vector of y data 
%  X3:  vector of x data 
%  Y3:  vector of y data 
 
%  Auto-generated by MATLAB on 04-Feb-2019 20:22:45 
 
% Create figure 
128 
 
figure1 = figure; 
 
% Create axes 
axes1 = axes('Parent',figure1,... 
    'ColorOrder',[1 0 0;0 0 1;0.666666666666667 0.333333333333333 
0;0.333333333333333 0.333333333333333 0.333333333333333;1 0 1;1 1 0;1 
0.666666666666667 0.333333333333333;0.666666666666667 0.666666666666667 
0.666666666666667;0.666666666666667 0.333333333333333 1;0 0.666666666666667 
0.333333333333333;0.666666666666667 0 0.333333333333333;1 0.333333333333333 
0.666666666666667;0 1 0;0.333333333333333 0.666666666666667 1;0.666666666666667 
1 0.333333333333333;0.333333333333333 0 0.666666666666667;0 0.333333333333333 
0.666666666666667;0.333333333333333 1 0.666666666666667;0 0 0;0.333333333333333 
0.666666666666667 0;0.333333333333333 0 0.666666666666667],... 
    'Tag','main'); 
hold(axes1,'on'); 
 
% Create plot 
plot(X1,Y1,'DisplayName','BSC Pacing (n=9)','Tag','dfdata',... 
    'MarkerIndices',[1 2 3 4 5 6 7 8 9 10 11 12 13 14],... 
    'LineWidth',1,... 
    'Color',[0 0.333333333333333 0.666666666666667]); 
 
% Create plot 
plot(X2,Y2,'DisplayName','MDT ICD (n=12)','Tag','dfdata',... 
    'MarkerIndices',[1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
23 24],... 
    'LineWidth',1,... 
    'Color',[0.666666666666667 1 0.333333333333333]); 
 
% Create plot 
plot(X3,Y3,'DisplayName','MDT Pacing (n=53)','Tag','dfdata',... 
    'MarkerIndices',[1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 
49 50 51 52 53 54],... 
    'LineWidth',1,... 
    'Color',[0.333333333333333 0.666666666666667 1]); 
 
% Create xlabel 
xlabel('Data'); 
 
% Create ylabel 
ylabel('Survivor function'); 
 
% Uncomment the following line to preserve the X-limits of the axes 
% xlim(axes1,[0.0551999999999999 190.2648]); 
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% Uncomment the following line to preserve the Y-limits of the axes 
% ylim(axes1,[0 1]); 
% Uncomment the following line to preserve the Z-limits of the axes 
% zlim(axes1,[0 1]); 
box(axes1,'on'); 
% Set the remaining axes properties 
set(axes1,'OuterPosition',[-0.00178571428571429 -0.00238095238095238 1 1]); 
% Create legend 
legend1 = legend(axes1,'show'); 
set(legend1,'Interpreter','none'); 
 
ICD leads survival probability 
function createfigure4(X1, Y1, X2, Y2) 
%CREATEFIGURE4(X1, Y1, X2, Y2) 
%  X1:  vector of x data 
%  Y1:  vector of y data 
%  X2:  vector of x data 
%  Y2:  vector of y data 
 
%  Auto-generated by MATLAB on 04-Feb-2019 20:34:24 
 
% Create figure 
figure1 = figure; 
 
% Create axes 
axes1 = axes('Parent',figure1,... 
    'ColorOrder',[1 0 0;0 0 1;0.666666666666667 0.333333333333333 
0;0.333333333333333 0.333333333333333 0.333333333333333;1 0 1;1 1 0;1 
0.666666666666667 0.333333333333333;0.666666666666667 0.666666666666667 
0.666666666666667;0.666666666666667 0.333333333333333 1;0 0.666666666666667 
0.333333333333333;0.666666666666667 0 0.333333333333333;1 0.333333333333333 
0.666666666666667;0 1 0;0.333333333333333 0.666666666666667 1;0.666666666666667 
1 0.333333333333333;0.333333333333333 0 0.666666666666667;0 0.333333333333333 
0.666666666666667;0.333333333333333 1 0.666666666666667;0 0 0;0.333333333333333 
0.666666666666667 0;0.333333333333333 0 0.666666666666667],... 
    'Tag','main'); 
hold(axes1,'on'); 
 
% Create plot 
plot(X1,Y1,'DisplayName','MDT ICD Leads (n=12)','Tag','dfdata',... 
    'MarkerIndices',[1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
23 24],... 
    'LineWidth',1,... 
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    'Color',[0 0.666666666666667 0.333333333333333]); 
 
% Create plot 
plot(X2,Y2,'DisplayName','BSC ICD Leads (n=3)','Tag','dfdata',... 
    'MarkerIndices',[1 2 3 4 5 6],... 
    'LineWidth',1,... 
    'Color',[0.666666666666667 0.333333333333333 1]); 
 
% Create xlabel 
xlabel('Months After Implant'); 
 
% Create ylabel 
ylabel('Survivor function'); 
 
% Uncomment the following line to preserve the X-limits of the axes 
% xlim(axes1,[4.602 147.198]); 
% Uncomment the following line to preserve the Y-limits of the axes 
% ylim(axes1,[0 1]); 
% Uncomment the following line to preserve the Z-limits of the axes 
% zlim(axes1,[0 1]); 
box(axes1,'on'); 
% Set the remaining axes properties 
set(axes1,'OuterPosition',[-0.00178571428571429 -0.00238095238095238 1 1]); 
% Create legend 
legend1 = legend(axes1,'show'); 
set(legend1,'Interpreter','none'); 
 
 
Pacing leads survival probability 
function createfigure3(X1, Y1, X2, Y2) 
%CREATEFIGURE3(X1, Y1, X2, Y2) 
%  X1:  vector of x data 
%  Y1:  vector of y data 
%  X2:  vector of x data 
%  Y2:  vector of y data 
 
%  Auto-generated by MATLAB on 04-Feb-2019 20:27:49 
 
% Create figure 
figure1 = figure; 
 
% Create axes 
axes1 = axes('Parent',figure1,... 
131 
 
    'ColorOrder',[1 0 0;0 0 1;0.666666666666667 0.333333333333333 
0;0.333333333333333 0.333333333333333 0.333333333333333;1 0 1;1 1 0;1 
0.666666666666667 0.333333333333333;0.666666666666667 0.666666666666667 
0.666666666666667;0.666666666666667 0.333333333333333 1;0 0.666666666666667 
0.333333333333333;0.666666666666667 0 0.333333333333333;1 0.333333333333333 
0.666666666666667;0 1 0;0.333333333333333 0.666666666666667 1;0.666666666666667 
1 0.333333333333333;0.333333333333333 0 0.666666666666667;0 0.333333333333333 
0.666666666666667;0.333333333333333 1 0.666666666666667;0 0 0;0.333333333333333 
0.666666666666667 0;0.333333333333333 0 0.666666666666667],... 
    'Tag','main'); 
hold(axes1,'on'); 
 
% Create plot 
plot(X1,Y1,'DisplayName','MDT Pacing (n=53)','Tag','dfdata',... 
    'MarkerIndices',[1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 
49 50 51 52 53 54],... 
    'LineWidth',1,... 
    'Color',[0 0 0]); 
 
% Create plot 
plot(X2,Y2,'DisplayName','BSC Pacing (n=9)','Tag','dfdata',... 
    'MarkerIndices',[1 2 3 4 5 6 7 8 9 10 11 12 13 14],... 
    'LineWidth',1,... 
    'Color',[0 0.333333333333333 0.666666666666667]); 
 
% Create xlabel 
xlabel('Months After Implant'); 
 
% Create ylabel 
ylabel('Survivor function'); 
 
% Uncomment the following line to preserve the X-limits of the axes 
% xlim(axes1,[0.0551999999999999 190.2648]); 
% Uncomment the following line to preserve the Y-limits of the axes 
% ylim(axes1,[0 1]); 
% Uncomment the following line to preserve the Z-limits of the axes 
% zlim(axes1,[0 1]); 
box(axes1,'on'); 
% Set the remaining axes properties 
set(axes1,'OuterPosition',[-0.00178571428571429 -0.00238095238095238 1 1]); 
% Create legend 
legend1 = legend(axes1,'show'); 
set(legend1,'Interpreter','none'); 
